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Abstract
Background—Progestin-only contraceptives (POCs) are appropriate for many women who 
cannot or should not take estrogen. POCs include injectables, intrauterine contraception, implants, 
and oral contraceptives. Many POCs are long-acting, cost-effective methods of preventing 
pregnancy. However, concern about weight gain can deter the initiation of contraceptives and 
cause early discontinuation among users.
Objectives—The primary objective was to evaluate the association between progestin-only 
contraceptive use and changes in body weight.
Search methods—Until 4 August 2016, we searched MEDLINE, CENTRAL, POPLINE, 
LILACS, ClinicalTrials.gov, and ICTRP. For the initial review, we contacted investigators to 
identify other trials.
Selection criteria—We considered comparative studies that examined a POC versus another 
contraceptive method or no contraceptive. The primary outcome was mean change in body weight 
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or mean change in body composition. We also considered the dichotomous outcome of loss or gain 
of a specified amount of weight.
Data collection and analysis—Two authors extracted the data. Non-randomized studies 
(NRS) need to control for confounding factors. We used adjusted measures for the primary effects 
in NRS or the results of matched analysis from paired samples. If the report did not provide 
adjusted measures for the primary analysis, we used unadjusted outcomes. For RCTs and NRS 
without adjusted measures, we computed the mean difference (MD) with 95% confidence interval 
(CI) for continuous variables. For dichotomous outcomes, we calculated the Mantel-Haenszel odds 
ratio (OR) with 95% CI.
Main results—We found 22 eligible studies that included a total of 11,450 women. With 6 NRS 
added to this update, the review includes 17 NRS and 5 RCTs. By contraceptive method, the 
review has 16 studies of depot medroxyprogesterone acetate (DMPA), 4 of levonorgestrel-
releasing intrauterine contraception (LNG-IUC), 5 for implants, and 2 for progestin-only pills.
Comparison groups did not differ significantly for weight change or other body composition 
measure in 15 studies. Five studies with moderate or low quality evidence showed differences 
between study arms. Two studies of a six-rod implant also indicated some differences, but the 
evidence was low quality.
Three studies showed differences for DMPA users compared with women not using a hormonal 
method. In a retrospective study, weight gain (kg) was greater for DMPA versus copper (Cu) IUC 
in years one (MD 2.28, 95% CI 1.79 to 2.77), two (MD 2.71, 95% CI 2.12 to 3.30), and three (MD 
3.17, 95% CI 2.51 to 3.83). A prospective study showed adolescents using DMPA had a greater 
increase in body fat (%) compared with a group not using a hormonal method (MD 11.00, 95% CI 
2.64 to 19.36). The DMPA group also had a greater decrease in lean body mass (%) (MD −4.00, 
95% CI −6.93 to −1.07). A more recent retrospective study reported greater mean increases with 
use of DMPA versus Cu IUC for weight (kg) at years 1 (1.3 vs 0.2), 4 (3.5 vs 1.9), and 10 (6.6 vs 
4.9).
Two studies reported a greater mean increase in body fat mass (%) for POC users versus women 
not using a hormonal method. The method was LNG-IUC in two studies (reported means 2.5 
versus −1.3; P = 0.029); (MD 1.60, 95% CI 0.45 to 2.75). One also studied a desogestrel-
containing pill (MD 3.30, 95% CI 2.08 to 4.52). Both studies showed a greater decrease in lean 
body mass among POC users.
Authors’ conclusions—We considered the overall quality of evidence to be low; more than 
half of the studies had low quality evidence. The main reasons for downgrading were lack of 
randomizations (NRS) and high loss to follow-up or early discontinuation.
These 22 studies showed limited evidence of change in weight or body composition with use of 
POCs. Mean weight gain at 6 or 12 months was less than 2 kg (4.4 lb) for most studies. Those 
with multiyear data showed mean weight change was approximately twice as much at two to four 
years than at one year, but generally the study groups did not differ significantly. Appropriate 
counseling about typical weight gain may help reduce discontinuation of contraceptives due to 
perceptions of weight gain.
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Medical Subject Headings (MeSH)
Body Composition [drug effects]; Body Weight [*drug effects]; Contraceptives, Oral, Hormonal 
[*pharmacology]; Levonorgestrel [*pharmacology]; Medroxyprogesterone Acetate 
[*pharmacology]; Progestins [*pharmacology]; Weight Gain [drug effects]
MeSH check words
Female; Humans
PLAIN LANGUAGE SUMMARY
Effects of progestin-only birth control on weight
Progestin-only contraceptives (POCs) can be used by women who cannot or should not take 
the hormone estrogen. Many POCs are long acting, cost less than some other methods, and 
work well to prevent pregnancy. Some people worry that weight gain is a side effect of these 
birth control methods. Concern about weight gain can keep women from using these 
methods. Further, some women may stop using birth control early, which can lead to 
unplanned pregnancy. We looked at studies of POCs and changes in body weight.
Until 4 August 2016, we did computer searches for studies of a POC compared with another 
birth control method or no contraceptive. For the initial review, we wrote to investigators to 
find other trials. The focus was on change in body weight or other body measure of lean or 
fat mass.
With six new studies in this update, we have 22 studies that included 11,450 women. The 
groups compared did not differ much for weight change or other body measures in 15 
studies. Five studies with moderate or low quality results showed a difference between study 
groups. Three studies showed differences for users of the injectable ‘depo’ versus no 
hormonal method. Depo users had a greater weight gain in two studies. In the third study, 
adolescents had a greater increase in body fat (%) and decrease in lean body mass (%). Two 
studies showed a greater increase in body fat (%) for users of hormonal intrauterine 
contraception versus women not using a hormonal method. One also showed a similar 
difference with a progestin-only pill. Both studies showed a greater decrease in lean body 
mass with POC use.
We found little evidence of weight gain when using POCs. Mean weight gain at 6 or 12 
months was less than 2 kg (4.4 lb) for most studies. The groups using other birth control 
methods had about the same weight gain. Good counseling about typical weight gain may 
help women continue using birth control.
BACKGROUND
Description of the condition
Many women consider weight gain a side effect of using hormonal contraceptives (Bartz 
2011; Raymond 2011). This perception may be based on self-report of side effects rather 
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than actual weight changes (Paul 1997; Berenson 2008; Nault 2013). Many clinicians and 
women believe that progestin-only contraceptives cause weight gain (WebMD 2010; 
Albright 2015).
Concern about weight gain can deter the initiation of contraceptives and cause early 
discontinuation among users. In a United States (US) study of bone mineral density, weight 
gain was reported more often by women using depot medroxyprogesterone acetate (DMPA) 
than those using a low-dose oral contraceptive (Berenson 2008). Weight gain was the most 
common side effect reported with DMPA use, after menstrual disturbances, in a New 
Zealand study (Paul 1997), and was the most common self-reported side effect in a study 
from Iran (Veisi 2013). Reported weight gain has been a major reason for discontinuing 
DMPA use in the US (Bonny 2004). Some evidence suggests that DMPA is a concern for 
adolescents who are already obese (Curtis 2009). From a survey of Latin American women 
across four countries, more women believed levonorgestrel-releasing intrauterine 
contraception (LNG-IUC) led to weight gain, mood swings, and infertility compared with 
copper IUC (Silva-Filho 2016). In a US study, more women reported weight gain as a side 
effect for the etonogestrel implant than for LNG-IUC (Dickerson 2013). Weight gain was 
also reported for levonorgestrel implants (Sivin 2003). The gain may have been greater 
among women in the US than among those in China, and may be partly attributable to 
differences in dietary habits.
Description of the intervention
Progestin-only contraceptives (POCs) include injectables, implants, hormonal intrauterine 
contraception (IUC), and pills. Except for the pills, POCs are longer-acting and help free 
women from daily action to prevent unintended pregnancy. Such methods are among the 
most cost-effective contraceptives in many areas. Studies of long-acting methods are often of 
longer duration than those for pills, making study of weight change over time more feasible.
POCs do not contain estrogen, unlike combined hormonal contraceptives that have both 
progestin and estrogen. Therefore, POCs are appropriate for women who cannot or should 
not take estrogen (ACOG 2006). In Medical Eligibility Criteria, POCs are category 1 for 
women who are obese (body mass index (BMI) ≥ 30 kg/m2) (CDC 2012b; WHO 2015a; 
WHO 2015b). Category 1 is a condition with no restriction for use of the contraceptive 
method. For obese adolescents, DMPA is category 2 due to possible effects on bone mineral 
density. For category 2, method advantages generally outweigh the theoretical or proven 
risks. POCs are also category 1 for breastfeeding women who are at least six weeks 
postpartum. Combined hormonal contraceptives are category 3 for such women until six 
months postpartum (WHO 2015b). In the US, CHCs are considered category 2 by one 
month postpartum (CDC 2012b).
Worldwide, intrauterine contraception (IUC) is the most commonly used reversible method 
among women married or in union (UN 2015). In the US in 2012, IUC use was low 
compared with oral contraceptive use (Guttmacher 2015). However, use of long-acting 
reversible methods (LARC) increased to 11.6% from 8.5% in 2009 (Kavanaugh 2015). 
Nearly three-fourths of IUC users were using hormonal IUC. Worldwide, the method used 
most frequently after IUC is oral contraceptives, which include combined oral contraceptives 
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(COCs) and progestin-only pills (POPs). In the least developed countries, injectables are 
most commonly used, followed by oral contraceptives (UN 2015). Some injectable 
contraceptives contain both estrogen and progestin, while others like DMPA are progestin-
only.
How the intervention might work
In general, weight gain is due to an increase in fluid retention, muscle mass, or fat 
deposition. Research on mechanisms for weight change include investigations related to 
contraceptive use. Two uncontrolled studies included DMPA initiators, 12 to 21 years old. In 
a six-month study with 43 DMPA users, weight increased 1.2 kg among African Americans, 
as did BMI and total body fat. However, appetite score decreased while on DMPA for both 
African American and white participants (Bonny 2004). A 12-month study with 45 young 
women looked for associations of reported dietary intake with body composition change 
(Lange 2015). BMI increased significantly over 12 months, i.e. 1.6 kg/m2, but was not 
associated with total energy intake or macronutrient composition of the diet (carbohydrates, 
fat, or protein). The study lost 31% of participants.
Other experimental studies included adult women. A nine-week study of resting metabolic 
rate (RMR) with DMPA initiation included 13 women with BMI 20 to 35 kg/m2. RMR 
increased significantly during the first three weeks compared with the next six, especially for 
those who initiated during the luteal cycle (Steward 2016). An increase in non-shivering 
thermogenesis was consistent with the RMR change. A six-month metabolic study of P-O 
methods focused on 25 obese women (BMI ≥ 30) (Bender 2013). Participants chose the 
levonorgestrel-releasing intrauterine system (LNG-IUS), the etonogestrel-releasing (ETG) 
implant, or a non-hormonal method. Fasting glucose increased and insulin sensitivity 
decreased more with the ETG implant than with the LNG-IUS when compared to a non-
hormonal method. An eight-week study examined DMPA effects on food motivation centers 
in the brain (Basu 2016). Eight of 14 women completed the protocol with data for analysis. 
All had BMI < 30 and most were Latina. The investigators used functional magnetic 
resonance imaging (MRI) to assess response to food cues. The blood oxygen level 
dependent signal was greater after eight weeks of DMPA compared with baseline. Some 
brain regions had significant activation after DMPA with food versus nonfood images and 
with high-calorie versus low-calorie food cues. Circulating leptin and ghrelin, hormones 
known to regulate eating behavior, did not change significantly. Such work may help 
elucidate mechanisms when conducted with larger sample sizes.
During adolescence, some weight gain is developmentally normal and appropriate. Also, 
people tend to gain weight over time (Flegal 2000). In the US, the prevalence of overweight 
or obesity is higher for men and women 40 to 59 years of age compared with those aged 20 
to 39 years (Ogden 2014). In contraceptive studies, weight change is rarely a primary 
outcome in contraceptive studies. No consensus exists regarding what is excessive weight 
gain. Examining contraceptive use and weight gain can be complicated by the initial weight 
of the users. Recent interest in the effectiveness of hormonal contraceptives among obese 
women has led to more research with such women, who had been historically excluded from 
such studies (Bender 2013; Lopez 2013; Edelman 2014).
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Concern about contraceptive effectiveness among overweight women (Robinson 2013; 
Merki-Feld 2015) has led to questions about contraceptive usage by overweight or obese 
women. An analysis of medical records from 231 health centers examined contraceptive use 
among 147,336 US women, age 15 to 44 years (Kohn 2015). The obese women (BMI ≥ 30) 
were more likely to use LARC than women with a BMI < 30 (13% versus 9%, respectively). 
Obese women were less likely than women with a lower BMI to use OCs, the injectable, the 
vaginal ring, or the subdermal patch (76% versus 82%, respectively). An analysis of US 
survey data examined contraceptive use in the past month (Callegari 2014). The women 
were sexually active, obese (BMI > 30), and age 20 to 44 years. LARC use among these 
obese women was nearly 10%, but only about 38% reported using OCs, the patch, the ring, 
or injectable contraception. While 21% reported not using a contraceptive method in the past 
month, 31% used a nonprescription method, i.e. condoms or another barrier method, 
withdrawal, or fertility awareness methods. Those two groups were more likely to be the 
youngest and oldest (aged 20 to 24 or 40 to 44). Women who used nonprescription methods 
were less likely to report having discussed contraception with a healthcare provider in the 
past year.
Why it is important to do this review
Prior to the initial review, no comprehensive systematic review existed on progestin-only 
contraceptives and weight change. Concern about weight gain might deter women from 
using these effective contraceptives and health care providers from recommending them. We 
did not examine effectiveness nor focus on overweight women. Many reviews have 
examined effectiveness of specific progestin-only contraceptives, such as progestin-only 
pills (Grimes 2013) and IUC (Grimes 2007). Further, a Cochrane review examined 
effectiveness of hormonal contraceptives for overweight women versus women who were 
not overweight (Lopez 2013).
Progestin-only contraceptives are an attractive option for many women. The longer-acting 
POCs, especially IUC and implants, are among the more effective methods with typical use 
(Trussell 2011). The cost for POCs can be less than that of COCs in some areas, and many 
postpartum women can use them. Further, POCs are appropriate for women at increased risk 
for venous thromboembolism such as those who are obese (Merki-Feld 2015), which is 
important given the worldwide epidemic of obesity (Prentice 2006; Flegal 2012; Ogden 
2014). Being overweight or obese increases also risk for Type 2 diabetes and other diseases 
and disorders.
OBJECTIVES
The primary objective was to evaluate the potential association between progestin-only 
contraceptive use and changes in body weight.
METHODS
Criteria for considering studies for this review
Types of studies—We considered studies that examined progestin-only contraceptives 
used for contraception and their associations with weight change. Reports had to contain 
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information on the specific contraceptive method(s) examined. We searched for studies with 
comparative data on a progestin-only contraceptive versus another contraceptive (differing in 
formulation, dose, regimen, or initiation time) or no hormonal contraceptive. Potential 
studies included comparisons of a POC with a combination contraceptive as well as 
comparisons of two different types of progestin-only contraceptives.
Types of participants—Participants were the women in the studies who used the 
progestin only contraceptive for contraception or who had the comparison intervention or 
placebo. We did not consider studies focused on women with specific health problems, such 
as diabetes or HIV.
Types of interventions—We considered any progestin-only contraceptive, such as an 
oral contraceptive, an injectable, an implant, or hormonal intrauterine contraception (IUC). 
Treatment duration must have been at least three cycles or three months.
The progestin method of interest must have been specified and not combined in a group with 
another method, e.g. a group that used either DMPA or norethisterone enanthate (NET-EN). 
The comparison could have been another progestin-only contraceptive or a group of 
contraceptives, such as COCs. We did not include comparison groups identified only as oral 
contraceptive (OC) users, since the oral contraceptives could have been progestin-only pills 
or combined oral contraceptives.
The progestin-only method had to be intended for contraception. We did not consider studies 
of contraceptives used for treatment for specific disorders, e.g. acne, hirsutism, or polycystic 
ovary syndrome.
Types of outcome measures—The primary outcome was the continuous outcome of 
mean change in body weight, BMI, or body composition (e.g. percent body fat) over time 
with the use of progestin-only contraceptives. If mean change in body weight or BMI was 
not available per study arm, we examined the dichotomous outcome of loss or gain of a 
specified amount of weight in each study arm.
For high quality evidence, the study had to include mean change in body weight, BMI, or 
body composition. The time frame had to be 12 months.
We used measured weight and not self-reported weight. We excluded studies that did not 
report change data but only reported mean weight or BMI at pre- and post-treatment.
Search methods for identification of studies
Electronic searches—Until 4 August 2016, we searched MEDLINE, Cochrane Central 
Register of Controlled Trials (CENTRAL), POPLINE, Web of Science, and LILACS. We 
also searched for trials via ClinicalTrials.gov and the search portal of the International 
Clinical Trials Registry Platform (ICTRP). Appendix 1 shows the 2016 strategies. We listed 
the previous search strategies in Appendix 2.
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Searching other resources—We examined reference lists of relevant articles. For the 
initial review, we contacted investigators in the field to seek additional unpublished trials or 
published trials that we may have missed in our search.
Data collection and analysis
Selection of studies—We assessed for inclusion all titles and abstracts identified during 
the literature searches. One author reviewed the search results and identified reports for 
inclusion or exclusion. A second author also examined the reports identified for appropriate 
categorization according to the eligibility criteria above.
We considered all comparative study designs. For example, studies could have been 
randomized controlled trials (RCTs), other prospective studies (provided intervention; 
assignment not random), observational studies of users, case-control studies, or retrospective 
chart reviews. We also considered post hoc analysis from any of these types of studies. 
However, the studies had to meet the Criteria for considering studies for this review.
Data extraction and management—Two authors conducted the data extraction. One 
author entered the data into Review Manager (RevMan 2014), and a second author checked 
accuracy. These data include the study characteristics, risk of bias, and outcomes. We 
focused on the primary and secondary outcomes for this review, which do not include all 
outcomes from each study. The authors resolved discrepancies through discussion.
Assessment of risk of bias in included studies—We examined the RCTs for 
methodological quality in accordance with recommended principles (Higgins 2011), and 
entered the information into the Risk of bias tables. Factors considered are randomization 
method, allocation concealment, blinding, and losses to follow-up and early discontinuation.
For the NRS, we used the Newcastle-Ottawa Quality Assessment Scale (NOS) (Higgins 
2011; Wells 2014). Of the two NOS versions, i.e. for case-control and cohort studies, the 
latter was more pertinent here (Appendix 3). The NOS investigators are examining the 
criterion validity and construct validity of this scale as well as the inter-rater reliability and 
intra-rater reliability. The scale does not yet have an overall scoring or threshold for a ’good’ 
or ’poor’ quality study. The NOS has eight items within three domains: selection 
(representativeness), comparability (due to design or analysis), and outcomes (assessment 
and follow-up). A study can receive one star (✴) for meeting each criterion. The exception is 
comparability (design or analysis), for which a study can receive two stars (for design and 
analysis). We adapted the NOS items for this project as suggested by the developers (Wells 
2014).
Measures of treatment effect—Outcomes listed in Characteristics of included studies 
focus on those relevant to this review. We examined weight change in relation to initial body 
weight or body mass index (BMI) [weight (kg)/height (m)2] when we had the necessary 
data. Weight change may differ for women who were initially overweight or obese versus 
those who were not. We preferred BMI over weight alone, as BMI is a better reflection of 
body fat (CDC 2012a). The measures and cutoffs depended on those used in the included 
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studies. Frequently used BMI categories are 25 to 29.9 (kg/m2) for overweight and 30 or 
higher for obesity (CDC 2012a).
We examined results by the contraceptive method studied, e.g. injectable or implant, as well 
as by formulation, dose, or regimen as appropriate. The main comparisons for this review 
were between users of progestin-only contraceptives and users of another contraceptive 
(differing in formulation, dose, or regimen) or no hormonal contraceptive.
For weight change measure with follow-up of less than one year, we selected the six-month 
assessment (if available) and the latest date. If multiple time points were reported up to one 
year, we used the 6- and 12-month data. If data were available for more than three years, we 
used one-year data, the midpoint, and the last measure.
Randomized trials: For continuous variables, we computed the mean difference (MD) with 
95% confidence interval (CI). Review Manager uses the inverse variance approach. For the 
dichotomous outcomes, we calculated the Mantel-Haenszel odds ratio (OR) with 95% CI. 
An example is the proportion of women who gained or lost more than 2 kg. Fixed and 
random effects give the same result if no heterogeneity exists, as when a comparison 
includes only one study.
Non-randomized studies: Given the need to control for confounding factors in NRS, we 
used adjusted measures for the primary effect measures when available or the results of 
matched analysis from paired samples. Investigators may have used a variety of adjustment 
strategies. When presenting results, we note the confounding factors considered in the 
design or analysis. If the report did not provide adjusted measures for the primary analysis, 
we used unadjusted outcomes with the methods described above for use with RCTs.
Dealing with missing data—We excluded studies with insufficient data on weight or 
BMI for analysis in this review. Reports sometimes provided results in figures without 
specific numbers; others presented means without any variance estimate. We contacted 
investigators for other missing data and for clarifications if the studies were less than 10 
years old or had a report within the past five years. Investigators are unlikely to have access 
to data from older studies. Many studies in the initial review were more than 10 years old.
Assessment of heterogeneity—We expected study populations, designs, and 
interventions to be heterogeneous. We described the clinical and methodological diversity 
(or heterogeneity) of the studies. We did not pool data from studies that had different 
contraceptive methods (e.g. DMPA or implants), different doses of the same method, or 
different criteria for reporting weight change. Therefore, we were not able to conduct meta-
analysis due to the range of contraceptive methods examined and different reporting for 
weight change. Heterogeneity is not an issue when a comparison has a single study.
Data synthesis—To assess the quality of evidence and address confidence in the effect 
estimates, we applied principles from GRADE (Grades of Recommendation, Assessment, 
Development and Evaluation) (Higgins 2011; GRADE 2013). If meta-analysis is not viable 
because of varied interventions or outcome measures, a typical ’Summary of findings’ table 
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is not feasible. Also, the criteria for quality assessment differ for NRS and RCTs. We 
provide ’Summary of findings’ tables for the main results, although we did not conduct a 
formal GRADE assessment for all outcomes (GRADE 2013).
We based our assessment of the body of evidence on the quality of evidence from the 
studies. In 2016, we revised the Risk of bias tables to accommodate RCTs and NRS. For the 
NRS, we used the Newcastle-Ottawa Quality Assessment Scale as noted earlier (Appendix 
3). Evidence quality included the design, implementation, and reporting of the study. We list 
the criteria for downgrading below.
1. Inadequate randomization sequence generation or allocation concealment, 
or no information provided for either one (RCT), or study was not 
randomized (NRS)
2. NRS: high risk of bias in selection (NOS) or retrospective study of 
selected cases
3. NRS: no stars for comparability (NOS), i.e. not controlling for relevant 
confounding
4. Follow-up less than 12 months for change in weight or BMI
5. Losses (by one year or primary endpoint if more than one year): loss to 
follow-up greater than 20%, combined loss to follow-up and 
discontinuation greater than 50%, or differential losses between groups 
(greater than 50% difference)
For the initial review in 2010 and the minor update in 2013, we used a basic process to 
assess evidence quality. For those versions, the initial grade was based on study design: 
RCTs were considered to provide high quality evidence; prospective non-randomized 
studies, moderate quality; and retrospective studies, low quality. Those ratings were then 
downgraded for high loss to follow-up and inappropriate exclusions after randomization.
Sensitivity analysis—We examined separately the studies that provided evidence of 
moderate or high quality.
RESULTS
Description of studies
Results of the search—The 2013 search produced 189 citations: 123 references from the 
database searches, 63 trials from the clinical trials sites, and 3 references from other sources. 
After reviewing the full text, we included one new study for a total of 16 studies. We 
excluded five studies and two secondary articles related to previously excluded studies. The 
remaining references were discarded after reviewing the titles and abstracts. From the 
clinical trials sites, we added three new trials to Ongoing studies.
The 2016 search produced 138 unduplicated references from the database searches (Figure 
1). With one item from another source, the total was 139. We discarded 122 citations based 
on title or abstract. After reviewing the full text of 17 articles, we excluded 9 reports (8 
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primary articles plus a secondary article). We included six new studies that involved six 
primary reports plus two secondary articles. Searches of recent clinical trials yielded 61 
unduplicated listings. Two studies are completed but have not yet produced full reports 
(Studies awaiting classification). We will assess them for inclusion when full reports are 
available. Two other trials are Ongoing studies.
Included studies—With 6 new studies in this update, 22 studies now met our inclusion 
criteria. Fifteen were prospective and seven were retrospective.
• 15 prospective studies
• ◦ 5 randomized controlled trials (WHO 1983; Salem 1988; Ball 
1991; Sivin 1998; Westhoff 2007)
◦ 10 non-randomized studies (NRS) (Tankeyoon 1976; Castle 
1978; Salem 1984; Bonny 2009; Dal’Ava 2012; Nyirati 2013; 
Vickery 2013; Dal’Ava 2014; Dos Santos 2014; Napolitano 
2015)
• 7 retrospective studies: NRS (Moore 1995; Taneepanichskul 1998; Espey 
2000; Sule 2005; Tuchman 2005; Pantoja 2010; Modesto 2015)
The studies examined four categories of progestin-only contraceptives (Table 2).
• Oral contraceptives (OCs) containing norethisterone 350 µg, 
levonorgestrel 30 µg, or desogestrel 75 µg
• Injectables
◦ depot medroxyprogesterone acetate (DMPA): 150 mg/mL 
versus 450 mg/mL (intramuscular) or versus 104 mg/0.65mL 
(subcutaneous)
◦ norethisterone enanthate (NET-EN) 200 mg
• Implants: levonorgestrel 6 capsules or 2 rods; etonogestrel 1 rod
• Levonorgestrel-releasing intrauterine contraception (LNG-IUC)
Comparison groups included no hormonal method or a non-hormonal contraceptive; a 
different formulation, regimen, or initiation time of the same POC; another POC; and a 
combined contraceptive or a supplement containing estrogen.
Studies were conducted in the USA, South America, Europe, Africa, and Asia; some were 
conducted on multiple continents. Publication dates covered nearly 50 years: five studies 
from 1976 to 1988; four from 1991 to 1998; five from 2000 to 2009; and eight from 2010 to 
2015. Duration of prospective follow-up or retrospective data collection was six months to 
two years for 16 studies, while four studies gathered data for three to five years of use, and 
two studies collected retrospective data for 10 years of use.
The studies included a total of 11,450 women with an average of 520 and a median about 
160. Six studies had fewer than 100 participants, seven had 100 to 222 participants, six 
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ranged from 400 to 1000 women, and three had more than 1000 women. A few had 
comparison groups not used in this review because they did not meet our inclusion criteria.
We were not able to examine weight change in relation to age. Earlier, we identified three 
studies focused on adolescents and young women. Bonny 2009 analyzed data from a larger 
study of hormonal contraceptives and bone mineral density. Moore 1995 and Tuchman 2005 
were retrospective chart reviews. A certain amount of weight gain is part of normal 
development for adolescents. None of the newer studies focused on young women. Studies 
that included both adolescents and adult women did not provide outcome data for age 
subgroups.
Risk of bias in included studies
Figure 2 summarizes our assessments for the overall review. Table 1 shows how we rated 
each study, and Figure 3 illustrates our assessment for each study. Because we adapted the 
Risk of bias tables to accommodate criteria for NRS, some categories are not relevant to an 
RCT or an NRS. In those cases, we left the cell empty rather than state ’not applicable’ to 
distinguish between ’unclear’ and no assessment.
Allocation—Of the five RCTs, two reported the method of randomization and allocation 
concealment (Salem 1988; Sivin 1998). The other three had no information on 
randomization method or allocation concealment (WHO 1983; Ball 1991; Westhoff 2007). 
Of the 17 NRS, one did not meet the NOS selection criteria (Taneepanichskul 1998).
Blinding—Two of the five RCTs had information on blinding. Ball 1991 was reportedly 
“single-blind” without any specifics. For one trial used in Westhoff 2007, the evaluators 
were blinded. For most studies, blinding was not feasible due to differences in the 
contraceptive methods or to women having chosen their contraceptive method in the NRS.
Incomplete outcome data—Of 22 studies, 18 had high risk of bias related to incomplete 
outcome data. Nine had loss to follow-up or discontinuation greater than 50% (Castle 1978; 
WHO 1983; Salem 1988; Ball 1991; Sivin 1998; Westhoff 2007; Nyirati 2013; Dal’Ava 
2014; Dos Santos 2014). In Tankeyoon 1976, loss differed substantially between groups. 
Seven retrospective studies may have selected charts for those with complete data and not 
accounted for losses (Moore 1995; Taneepanichskul 1998; Espey 2000; Sule 2005; Tuchman 
2005; Pantoja 2010; Modesto 2015). Modesto 2015 also had differential losses across group 
that varied over time. Vickery 2013 recruited women who completed at least 11 months of 
use.
Selective reporting—After randomization, Taneepanichskul 1998 excluded women who 
developed a chronic disease or disorder during method use. This exclusion may have biased 
the results. Weight gain is associated with development of some diseases and disorders.
Other potential sources of bias
NRS: comparability (NOS): Of 17 non-randomized studies, eight addressed potential 
confounding factors. Four considered confounding in the design by matching on age and 
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baseline BMI (Pantoja 2010; Dal’Ava 2012; Dos Santos 2014) or age and weight (Dal’Ava 
2014). Four studies conducted analysis that adjusted for potential confounders (Moore 1995; 
Bonny 2009;Modesto 2015; Vickery 2013). In some cases, a comparison group did not meet 
our inclusion criteria, so we did not include that group in this review. Details are in 
Characteristics of included studies.
Effects of interventions
See: Summary of findings for the main comparison; Summary of findings 2; Summary of 
findings 3
We grouped results according to four types of progestin-only contraceptives studied, though 
some studies included more than one progestin-only (P-O) method. Table 2 summarizes the 
study interventions and outcomes, along with the mean changes in weight or other body 
composition measure. Two studies examined progestin-only pills, 15 addressed DMPA, 5 
investigated implants, and four evaluated LNG-IUC. We subdivided the DMPA studies into 
those comparing DMPA with a combination contraceptive, another progestin-only injectable 
formulation or regimen, or no hormonal contraception.
Progestin-only oral contraceptives—Two studies examined P-O oral contraceptives. 
In the RCT of Ball 1991, weight change at six months did not differ significantly between 
the norethisterone 350 µg and the levonorgestrel 30 µg groups (Analysis 1.1). Mean changes 
were small. The NRS of Napolitano 2015 compared body composition changes at 12 months 
for perimenopausal women receiving desogestrel 75 µg versus a control group with no 
hormonal treatment. The study also examined LNG-IUS. Changes in mean weight and BMI 
did not differ significantly between the OC group and the control group at 12 months 
(Analysis 2.1; Analysis 2.2). However, the desogestrel group had a greater increase in fat 
mass (%) (MD3.30, 95% CI 2.08 to 4.52) (Analysis 2.3).
Injectables
DMPA versus a combination contraceptive: Three NRS examined DMPA 150 mg/mL 
versus a contraceptive or supplement that also contained estrogen.
• In the small study of Tankeyoon 1976, the DMPA and COC groups were 
not significantly different in the proportions that gained (or lost) at least 1 
kg by months 6 and 12 (Analysis 3.1 to Analysis 3.4).
• The retrospective study of Tuchman 2005 focused on adolescents and 
young women, age 12 to 21 years. At 6 and 12 months, weight changes 
were not significantly different between the DMPA group and the COC 
users (Analysis 3.5 to Analysis 3.8) or the group using 
medroxyprogesterone acetate (MPA) plus E2C (Analysis 4.1 to Analysis 
4.4).
• Bonny 2009 compared mean changes in total body fat (%) and lean body 
mass (%) at six months for DMPA 150 + placebo injection versus DMPA 
+ estradiol cypionate 5 mg (E2C). The study targeted adolescents, age 12 
to 18 years. The DMPA group was not significantly different from the 
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DMPA plus E2C group for mean change in percent body fat or percent 
lean body mass (Analysis 5.1; Analysis 5.2).
DMPA versus another P-O injectable formulation or regimen: Of five studies in this 
group, three compared DMPA 150 mg/mL with other DMPA formulations or regimens. In 
Castle 1978, the mean changes in weight at six months were small and did not differ 
significantly between the DMPA 150 and DMPA 450 groups (Analysis 6.1). The 
retrospective study of Espey 2000 did not show a significant difference in weight gain at one 
or two years for those who initiated DMPA at 20 weeks or more after pregnancy (interval 
group) compared with those who initiated at 5 to 8 weeks (postpartum group) (Analysis 7.1; 
Analysis 7.2). In the RCT analyzed in Westhoff 2007, weight change was comparable for the 
group with intramuscular DMPA 150 and the group with subcutaneous DMPA 104 
(Analysis 8.1).
Two RCTs examined DMPA 150 mg/mL versus NET-EN 200 mg. In WHO 1983, mean 
weight changes at 12 and 24 months did not differ significantly between the DMPA group 
and with the group administered NET-EN at 60-day intervals (Analysis 9.1; Analysis 9.2). 
Salem 1988 did not report the units for weight (lb or kg). However, the DMPA and the NET-
EN groups did not differ significantly for mean changes in weight at one year (Analysis 9.3). 
Also in WHO 1983, two NET-EN regimens of 60 day-intervals versus 84-day intervals did 
not cause a significant difference in weight change (Analysis 10.1; Analysis 10.2).
DMPA versus no hormonal contraceptive: Eight NRS compared DMPA 150 mg/mL 
versus no hormonal method. Six had copper (Cu) IUC users as the comparison group; three 
studies were retrospective (Taneepanichskul 1998; Pantoja 2010; Modesto 2015) and three 
were prospective (Vickery 2013; Dal’Ava 2014; Dos Santos 2014). The remaining two 
prospective studies had other comparison groups (Bonny 2009;Nyirati 2013).
DMPA versus Cu IUC
Retrospective studies
• Taneepanichskul 1998 did not show a significant difference in weight 
change between the DMPA and Cu IUC groups at 10 years (Analysis 
11.1). Unlike most studies in this review, the participants did not include 
younger women. All were 37 to 50 years old.
• For Pantoja 2010, mean weight gain (kg) was greater for the DMPA group 
versus the Cu IUC group at years one (MD 2.28, 95% CI 1.79 to 2.77) 
(Analysis 11.2), two (MD 2.71, 95% CI 2.12 to 3.30) (Analysis 11.3), and 
three (MD 3.17, 95% CI 2.51 to 3.83) (Analysis 11.4). Per year, the mean 
weight changes for the DMPA group ranged from 1.76 kg to 3.9 kg, while 
changes within the IUC group were less than 1 kg (Analysis 11.5). For 
each year, the difference between contraceptive groups was notable within 
the normal to lower weight group (BMI < 25) and within the overweight 
group (BMI 25 to 29.9), but not within the obese group (BMI ≥ 30).
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• Modesto 2015 examined cumulative weight changes over 10 years of 
uninterrupted use of DMPA versus the Cu IUC. Using a generalized linear 
mixed model, the investigators adjusted for years of school and number of 
children. The adjusted analysis indicated mean weight change was 
significantly greater for the DMPA group versus the Cu IUC group for the 
three time points we used. The reported adjusted means were: at 1 year, 
1.3 versus 0.2 (P < 0.0001; Analysis 12.1); at 4 years, 3.5 versus 1.9 (P < 
0.0001; Analysis 12.2); at 10 years, 6.6 versus 4.9 (P < 0.0350; Analysis 
12.3). By four years, the DMPA and LNG-IUC group lost more than 20%; 
by 10 years, overall loss was 84%. The groups had differential losses at all 
three time points.
Prospective studies: 
• Vickery 2013 was a substudy within CHOICE, a prospective study of 9256 
women who received contraceptives at no cost. The investigators of the 
substudy examined weight change among women who had been 
continuous users of DMPA or the copper IUC for 11 months or longer. 
With a linear regression model, the investigators adjusted for the potential 
confounders of age and race. Weight change was not significantly different 
for use of DMPA compared with the Cu IUC (Analysis 12.4).
• Study designs were similar in Dal’Ava 2014 and Dos Santos 2014. While 
Dal’Ava 2014 paired participants in the DMPA and Cu IUC groups by age 
(± 2 years) and weight (± 2 kg), Dos Santos 2014 matched by age (± 1 
year) and BMI (± 1 kg/m2). The regression model in Dal’Ava 2014 
included the potential confounders of physical activity, consumption of 
coffee and alcohol, and smoking in regression. At 12 months, the study 
arms did not differ significantly for changes in total body mass (weight), 
fat mass, or lean mass in either study (Analysis 11.6). A secondary report 
from Dos Santos 2014 (Modesto 2014) included 29 women using DMPA 
and 25 using the Cu IUC. Multiple linear regression adjusted for potential 
confounders such as age, schooling, and pregnancies. DMPA use was 
significantly associated with change in total fat mass compared with Cu 
IUC use by 12 months (reported beta 2.09 ± SE 0.58; P < 0.002) but was 
not associated with change in percent body fat.
DMPA versus no hormonal method—Two studies compared women using DMPA to 
another group using no hormonal method.
• Bonny 2009, mentioned above, also compared adolescents using DMPA 
150 versus those using no hormonal method. By six months, the DMPA 
group had a greater increase in percent body fat (MD 11.00, 95% CI 2.64 
to 19.36) (Analysis 13.1) and a greater decrease in percent lean body mass 
(MD −4.00, 95% CI −6.93 to −1.07) (Analysis 13.2).
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• Nyirati 2013 compared DMPA at six weeks versus surgical sterilization 
among postpartum women, age 18 or older. By one year postpartum, the 
study arms did not differ significantly for change in weight, BMI, or 
percent body fat (Analysis 13.3 to Analysis 13.5). The sample size for the 
sterilization group was much smaller than that of the DMPA group.
Implants
Five studies examined implants, one RCT and four NRS. A 2013 report compared the 
single-rod etonogestrel (ENG) implant versus the copper IUC. Four older studies compared 
Norplant (six capsules) versus a non-hormonal IUC or another progestin-only contraceptive.
Vickery 2013, mentioned above with DMPA, also examined weight change over 12 months 
for the single-rod etonogestrel (ENG) implant versus the copper IUC. In the regression 
model adjusted for age and race, the ENG implant was not significantly associated with 
weight change compared with the Cu IUC (Analysis 12.4).
• Two studies utilized a non-hormonal IUC as the comparison.
◦ In a study with lactating women, Salem 1984 showed a greater 
weight gain (kg) at six months for the Norplant group versus 
the Cu IUC group (MD 0.47, 95% CI 0.29 to 0.65) (Analysis 
14.1). The Norplant group also had a greater weight gain (kg) 
than the group that used barrier, ’local,’ or no contraceptive 
method (MD 0.74, 95% CI 0.52 to 0.96) (Analysis 15.1).
◦ For the retrospective study of Sule 2005, the Norplant group 
had a significantly greater weight increase (kg) than the group 
with a non-hormonal IUC at one year (MD 1.10, 95% CI 0.36 
to 1.84) (Analysis 14.2) but not at three years (Analysis 14.3). 
The same study compared the Norplant group versus a group 
using COCs. Weight change did not differ significantly 
between the groups at one year (Analysis 18.1). At three years, 
the COC group had only two participants.
• The retrospective study of Moore 1995 targeted adolescents and young 
women, ages 15 to 30 years. The Norplant and DMPA groups were not 
significantly different in mean weight change at one year (Analysis 16.1).
• In the RCT of Sivin 1998, mean weight change was not significantly 
different for the Norplant group versus the two-rod implant group at one, 
three, or five years (Analysis 17.1; Analysis 17.2; Analysis 17.3).
Levonorgestrel-releasing intrauterine contraception (LNG-IUC)
Four NRS examined the LNG-IUC versus the non-hormonal Cu IUC or no treatment.
• Dal’Ava 2012 compared body composition changes with LNG-IUC versus 
with the Cu IUC. The two groups were paired by age (± 2 years) and BMI 
(± 2 kg/m2). At 12 months, the LNG-IUC group differed in percent change 
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in body fat mass compared with Cu IUC group (reported means 2.5% 
versus −1.3%; P = 0.029) (Analysis 19.1). The LNG-IUC group also 
differed from the Cu IUC users in percent change in lean body mass 
(reported means 1.4% versus 1.0%; P = 0.027).
• In addition to DMPA and the ENG implant, Vickery 2013 also examined 
LNG-IUC versus the Cu IUC. The linear regression model indicated 
weight change with the LNG-IUC was not significantly different at 12 
months from that with the non-hormonal IUC (Analysis 12.4).
• In addition to examining weight change with DMPA use (above), Modesto 
2015 compared weight change with LNG-IUC versus that with the Cu 
IUC. The study groups did not differ significantly for mean weight gain 
(kg) at 1 and 10 years after adjusting for years of school and number of 
children (Analysis 12.1; Analysis 12.3). As noted above for DMPA, losses 
were high and differential across groups.
• Besides an OC containing desogestrel (above), Napolitano 2015 also 
compared body composition changes at 12 months for perimenopausal 
women using LNG-IUC versus a control group receiving no hormonal 
treatment. In unadjusted analysis, change in mean weight or BMI did not 
differ significantly between the LNG-IUC group and the control group at 
12 months (Analysis 19.2; Analysis 19.3). However, compared with the 
control group, the LNG-IUC group had a greater mean increase in percent 
fat mass (MD 1.60, 95% CI 0.45 to 2.75) (Analysis 19.4) and therefore a 
greater mean decrease in fat free mass (MD −1.60, 95% CI −2.75 to 
−0.45) (Analysis 19.5).
DISCUSSION
Summary of main results
Actual mean weight gain at 6 or 12 months was limited, i.e. less than 2 kg for most studies 
up to one year (Table 2). The six studies with multiyear data showed that mean weight 
change was approximately twice as much at two to four years compared with one year, but 
generally the study groups did not differ significantly. These studies and their years of data 
included two RCTs (WHO 1983 [2 years]; Sivin 1998 [5 years]) and four retrospective 
studies (Espey 2000 [2 years]; Sule 2005 [3 years]; Pantoja 2010 [3 years]; Modesto 2015 
[10 years]). Another RCT (Westhoff 2007) and a retrospective study (Taneepanichskul 1998) 
had data from 3 and 10 years of use, respectively, but not multiyear data.
In Table 3, we synthesized the results for each contraceptive category. Overall, 7 of the 22 
included studies indicated a significant difference between groups for change in weight, 
body fat, or fat free mass (Salem 1984; Sule 2005; Bonny 2009; Pantoja 2010; Dal’Ava 
2012;Modesto 2015;Napolitano 2015).Three examined DMPA, two studied the LNG-IUC, 
two focused on Norplant (six capsules), and one examined a desogestrel OC. The 
comparisons were groups using no hormonal method.
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Summary of findings tables
This section focuses on the five studies with evidence of moderate or low quality that 
showed a significant difference between study arms (Table 3). Of 16 studies that examined 
DMPA (aside from one that also studied Norplant), three indicated an association between 
DMPA use and greater change in weight or other body composition measure (Summary of 
findings for the main comparison). Bonny 2009 was a small study of adolescents from a 
larger trial. Compared with a group using no hormonal contraceptive, the DMPA group had 
a greater increase in body fat percentage and a greater decrease in lean body mass. In 
Pantoja 2010, a retrospective study, mean weight gain was greater for the DMPA group 
versus the copper IUC group at one, two, and three years. The differences were notable 
within the normal to lower weight group and the overweight group but not within the obese 
group. For Modesto 2015, also retrospective, mean weight change was greater for the DMPA 
group compared with the copper IUC group at 1, 4, and 10 years, the three time points we 
examined. Four studies compared the LNG-IUC with a group not using any hormonal 
contraceptives. Two showed the study arms differed in body composition change by one 
year (Summary of findings 2), though they did not differ significantly for weight change. 
Within Dal’Ava 2012, participants using the LNG-IUC reportedly had a greater increase in 
fat mass (%) and a decrease in lean mass (%) compared with the non-hormonal IUC users. 
Similarly, in Napolitano 2015, the LNG-IUC group had a greater mean increase in fat mass 
(%) and a decrease in fat free mass (%) compared with the no-hormonal group.
One of two studies that examined P-O oral contraceptives showed an association between 
the OC and body composition change (Summary of findings 3). Napolitano 2015 compared 
use of an OC containing desogestrel 75 µg versus no hormonal contraceptive. The OC group 
showed the same pattern as the LNG-IUC group noted above, i.e. a greater mean increase in 
fat mass (%) and a decrease in fat free mass (%).
Overall completeness and applicability of evidence
Of the 22 included studies, 18 had data from a year or more of contraceptive use and 8 of 
those had data from two or more years. Weight gain (or the perception of weight gain) is 
frequently cited as a reason for discontinuing a contraceptive method. If a contraceptive 
method is associated with weight gain, a year is long enough to detect some change, though 
the amount may not be clinically significant. Of the eight studies with data from two or more 
years of contraceptive use, most showed the study groups did not differ significantly for 
weight gain, regardless of whether the comparison group used a progestin-only 
contraceptive or no hormonal method.
Within contraceptive method group, the studies varied in their comparison groups over time. 
Earlier DMPA studies generally compared DMPA with a hormonal contraceptive. Of the six 
studies added in this update, five compared DMPA with a non-hormonal IUC. For 
levonorgestrel-releasing intrauterine contraception, three of the four included studies were 
new. All four compared LNG-IUC with no hormonal method; in addition, two studied 
DMPA and one examined a P-O oral contraceptive. Overall, two studies of P-O pills met our 
inclusion criteria. We did not find any eligible studies of the progesterone-releasing vaginal 
ring.
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We do not have much evidence regarding weight change with currently marketed implants. 
Many studies of such implants did not meet our inclusion criteria, mainly due to the lack of 
comparative data on weight change. Two exceptions were a recent study of the etonogestrel-
releasing implant and one that compared Norplant (six capsules) with a two-rod implant. 
Most of the weight change data for implants in this review came from studies of Norplant, 
which is no longer marketed.
Quality of the evidence
We assessed the quality of evidence as noted earlier (Assessment of risk of bias in included 
studies). Table 1 has a summary based on the factors used in our assessment. We considered 
the overall quality of evidence to be low, given that evidence from12 of the 22 studies was 
low. Three studies provided moderate quality evidence and seven had very low quality 
evidence. We downgraded the 17 NRS for lack of randomization and three RCTs for 
insufficient information on randomization and allocation concealment. Most studies had 
high loss to follow-up or were retrospective studies that may not have accounted for losses to 
follow-up or early discontinuation.
Potential biases in the review process
We selected studies that had data on mean change in weight or other body composition 
measure. Several excluded studies did not report the data we needed. For the initial review, 
many studies were older, which limited our ability to obtain additional information from the 
investigators.
Agreements and disagreements with other studies or reviews
As noted earlier, many concerns about weight gain with POC use are based on perceptions 
and discontinuation reasons rather than measures of actual weight change. We found limited 
evidence of significant change for POC users versus those who did not use hormonal 
contraceptives. Actual weight gain was less than 2 kg (4.4 lb) up to one year. Another review 
showed no clear evidence of weight gain with the use of combined hormonal contraceptives 
(Gallo 2014). People may gain weight over time regardless of contraceptive use.
Two studies compared perceived weight gain with actual weight gain among POC users. In a 
substudy of the CHOICE project, women who perceived weight gain of 5 lb or more had a 
mean weight change of 10 lb by 12 months, which is about 8 lb more than those who did not 
perceive a gain (Nault 2013). Risk of perceived gain was greater for the POC group versus 
the Cu IUC group. However, Vickery 2013, another substudy of CHOICE, did not show a 
difference in weight change by 12months between the POC groups and the Cu IUC group. A 
secondary analysis of data from an RCT compared users of a two-rod levonorgestrel implant 
versus women who did not yet receive the implant (Gallo 2016). Perceived weight gain was 
more common in the implant arm compared with the control group. Women with perceived 
weight gain in the implant group were more likely to have a gain of 2 kg by three months. 
The proportions of women who gained 2 kg did not differ significantly between the two 
groups nor did median weight gain.
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Reviews have suggested that DMPA and weight gain may be a concern for women who are 
already obese, whether they are adolescents (Curtis 2009) or adults (Merki-Feld 2015). The 
review with three studies on adolescents considered the quality of evidence to be fair for two 
studies. They lacked numbers for those discontinued due to weight gain and did not have a 
non-hormonal comparison. The third study lost 37% of DMPA users by 18 months, thus 
producing high risk of bias. A retrospective study of adult women in this review showed that 
mean weight gain did not differ significantly between the DMPA and Cu IUC groups within 
the obese subgroup (Pantoja 2010). Within the normal and overweight subgroups though, 
weight gain was greater for the DMPA group. We included three studies of young women, 
but none with adolescents who were obese. One showed an increase in total body fat and a 
decrease in lean body mass for adolescents in the DMPA group compared with those in a 
non-hormonal group (Bonny 2009).
A review of adverse events examined whether early weight among DMPA users was 
associated with later weight gain (Steenland 2013). The researchers concluded weight 
change greater than 5% of baseline weight was associated with greater mean change in 
weight or BMI at follow-up. Two studies grouped DMPA users by early weight gain in 
secondary analysis from studies of bone mineral density. One study explored whether a 5% 
weight change in 6 months predicted weight change by 36 months (Le 2009). The original 
study lost 60% of DMPA users by 12 months and 76% by 36 months, leading to high risk of 
bias for the results. Predictors of early weight gain, among the 60% participating at six 
months, were a BMI < 30 and a reported increase in appetite. The second study was 
apparently based on a study that lost 24% by 12 months and 43% by 24 months; the report 
did not include the sample sizes at 6, 12, or 18 months (Bonny 2011). Of participants in the 
study at 12 or 18 months, baseline characteristics may have differed between those with 5% 
weight gain at six months and those with less weight gain.
AUTHORS’ CONCLUSIONS
Implications for practice
We found limited evidence of weight gain when using progestin-only contraceptives. We 
identified some significant differences when a P-O method was compared with no hormonal 
contraceptive. This includes studies of a P-O oral contraceptive, DMPA, levonorgestrel IUC, 
and an older implant.
Overall, actual mean weight gain was low for 6 to 12 months, i.e. less than 2 kg (4.4 lb) in 
most studies. More weight gain was noted at two and three years, but the comparison groups 
did not differ much for weight change. People may gain weight over time regardless of 
contraceptive use. Appropriate and accurate counseling about typical weight gain may help 
reduce discontinuation of contraceptives due to perceptions of weight gain.
Implications for research
Five studies with moderate or low quality evidence showed a significant difference between 
study arms. They examined DMPA, LNG-IUC, and a P-O pill versus no hormonal method 
use. All included a group not using a hormonal method. The outcomes were change in 
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weight, percent body fat, or percent lean body mass. Three were prospective non-
randomized studies and two were retrospective chart reviews. The overall quality of 
evidence was low, largely due to the lack of randomization and high losses.
Weight change is rarely the focus of prospective contraceptive studies. Some of the newer 
prospective studies did focus on change in weight or body composition. Well-designed 
RCTs assessing weight change over time would better address this issue. Comparisons could 
be between a P-O method and a non-hormonal group. However, careful counseling and 
follow-up are needed to avoid the high losses to follow-up and discontinuation found in 
many contraceptive studies.
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APPENDICES
Appendix 1. Search 2016
MEDLINE via PubMed (1 January 2013 to 4 August 2016)
(contraceptive agents, female[Mesh] OR contraceptive devices, female[Mesh] OR 
contracept*) AND (progest* OR “progestin only” OR “progestin only” contracept* OR 
“progestin only pill” OR progestin* OR progesteron* OR progestational, hormones, 
synthetic OR progestogen* OR medroxyprogesterone OR DMPA OR (levonorgestrel-
releasing AND intrauterine) OR “intrauterine device” OR “intrauterine contraception” OR 
IUD OR IUC OR (etonogestrel-releasing AND implant) OR (ETG AND implant) OR 
progesterone OR gestagen OR “progestogen only”) AND (body mass index OR BMI OR 
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weight) NOT (cancer[ti] OR polycystic [ti] OR exercise [ti] OR physical activity[ti] OR 
postmenopaus*[ti])
CENTRAL (Cochrane Central Register of Controlled Trials 2016, issue 1 (23 
February 2016))
Abstract: weight OR body mass index OR BMI
AND Title, Abstract, Keywords: contraception OR contraceptive
NOT Record Title: premenstrual OR dysmenor* OR endometr* OR *androgen* OR HIV 
OR polycystic OR PCOS OR cancer OR exercise OR anorexi* OR bulimi*
NOT Record Title: postmenopausal OR post-menopausal OR hormone therapy OR male 
hormonal OR male contracept* OR testosterone
Publication Year from 2013 to 2015 in Trials
POPLINE (2013 to 2016 (23 February 2016))
Keyword: Body Weight
AND Keyword: Contraceptive Agents Progestin
Web of Science (24 March 2016)
TOPIC:(contracept*) AND TOPIC:(overweight OR obese OR obesity OR body mass index 
OR BMI)
NOT TITLE: (cancer OR polycystic OR PCOS OR diabetes OR exercise OR physical 
activity OR postmenopaus* OR hormone therapy OR replacement)
Refined by: RESEARCHAREAS: (OBSTETRICS GYNECOLOGY OR 
PHARMACOLOGY PHARMACY OR ENDOCRINOLOGY METABOLISM) AND 
DOCUMENT TYPES: (ARTICLE)
Timespan: 2013–2016.
Search language=Auto
LILACS via VHL Regional Portal (29 March 2016)
tw:((tw:((tw:(“contraceptive agents female”)) OR (tw:(contracept*)))) AND (tw:(weight OR 
overweight OR obes* OR “body mass index”))) AND (instance:“regional”) AND (db:
(“LILACS”)
AND limit:(“female”)
AND year˙cluster:(“2012” OR “2013” OR “2014” OR “2015”))
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[Note: no listing for 2016]
ClinicalTrials.gov (7 March 2016)
Search terms: overweight OR obese OR obesity OR weight OR body mass index OR BMI
Condition: NOT (HIV OR polycystic OR PCOS OR cancer OR anorexia OR pulmonary OR 
metabolic OR amenorrhea)
Intervention: contraceptive OR contraception OR contraceptives
Gender: studies with female participants
First received: From 1 December 2012 to 16 October 2015
ICTRP (29 March 2016)
Condition: contraceptive OR contraception
AND Intervention: progestin OR progestin-only OR IUD OR implant OR 
medroxyprogesterone OR norethisterone
Recruitment status: All
Date of registration is between 1 December 2012 and 29 March 2016
Appendix 2. Previous searches
2013
MEDLINE via PubMed (1 January 2010 to 5 June 2013)
(contraceptive agents, female[Mesh] OR contraceptive devices, female[Mesh] OR 
contracept*) AND (progest* OR “progestin only” OR “progestin only” contracept* OR 
“progestin only pill” OR progestin* OR progesteron* OR progestational, hormones, 
synthetic OR progestogen* OR progesterone OR gestagen OR “progestogen only”) AND 
(body weight changes OR weight gain OR weight loss OR body mass index OR BMI OR 
weight) NOT (cancer[ti] OR polycystic [ti] OR exercise [ti] OR physical activity[ti] OR 
postmenopaus*[ti])
limited to human, female
CENTRAL (2010 to 1 June 2013)
weight OR body mass index OR BMI in Abstract
AND contraception OR contraceptive in Title, Abstract or Keywords
NOT premenstrual OR dysmenor* OR endometr* OR *androgen* OR HIV OR polycystic 
OR PCOS OR cancer OR exercise OR anorexia OR bulimic in Record Title
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NOT postmenopausal OR post-menopausal OR hormone therapy OR male hormonal OR 
male contracept* OR testosterone in Record Title
POPLINE (2010 to 26 December 2012)
Global: weight OR BMI OR body mass index
Keyword: contraceptive agents, progestin OR Low-Dose Progestins
Filter: research report
LILACS (2010 to 26 December 2012)
contraceptive agents or Agentes Anticonceptivos Femeninos or Anticoncepcionais 
Femininos or contraceptive devices, female or Dispositivos Anticonceptivos Femeninos or 
Dispositivos Anticoncepcionais Femininos or contraceptives or Anticonceptivos or 
Anticoncepcionais [Words]
AND weight or body weight or Peso Corporal or weight gain or Aumento de Peso or Ganho 
de Peso or weight reduction or weight loss or Pérdida de Peso or Perda de Peso or body 
weight changes or Cambios en el Peso Corporal or Alterações do Peso Corporal or body 
mass index or BMI [Words]
ClinicalTrials.gov (1 January 2010 to 26 December 2012)
Search terms: overweight OR obese OR obesity OR weight OR body mass index OR BMI
Condition: NOT (HIV OR polycystic OR PCOS OR cancer OR anorexia OR pulmonary OR 
metabolic OR amenorrhea)
Intervention: contraceptive OR contraception
Study type: interventional studies
Gender: studies with female participants
ICTRP (2010 to 26 December 2012)
1. Intervention: contraceptive OR contraception
2. Condition: contraceptive OR contraception
Intervention: progestin OR progestin-only OR IUD OR implant OR medroxyprogesterone 
OR norethisterone
2010
MEDLINE via PubMed (through 11 June 2010)
(contraceptive agents, female[Mesh] OR contraceptive devices, female[Mesh] OR 
contracept*) AND (progest* OR “progestin only” OR “progestin only” contracept* OR 
“progestin only pill” OR progestin* OR progesteron* OR progestational, hormones, 
synthetic OR progestogen* OR progesterone OR gestagen OR “progestogen only”) AND 
Lopez et al. Page 24
Cochrane Database Syst Rev. Author manuscript; available in PMC 2017 August 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(body weight changes OR weight gain OR weight loss OR body mass index OR BMI OR 
weight) NOT (cancer[ti] OR polycystic [ti] OR exercise [ti] OR physical activity[ti] OR 
postmenopaus*[ti])
limited to human, female
POPLINE (through 19 May 2010)
(progestin only contracept*/ contraceptive agents, progestin/low-dose progestins) & (weight/
weight gain/weight loss/body weight/BMI/body mass index/ weight change)
CENTRAL (through 19 May 2010)
weight OR body mass index OR BMI in Abstract and contraception OR contraceptive in 
Title, Abstract or Keywords
NOT premenstrual OR dysmenor* OR endometr* OR *androgen* OR HIV OR polycystic 
OR PCOS OR cancer OR exercise OR anorexia OR bulimic in Record Title
NOT postmenopausal OR post-menopausal OR hormone therapy OR male hormonal OR 
male contracept* OR testosterone in Record Title
EMBASE (through 15 June 2010)
(contraceptive agent, progestin --side effects
or
((contraceptive device or contraceptives or contracept*) and (gestagen! or progest? or 
progestin? or progesterone? or progestational, hormones, synthetic or progestogen?or 
progestin()only or progestin()only()contracept or progestin()only()pill or 
progestogen()only)))
and
(body weight! or weight gain or weight reduction or weight()loss or body()mass()index)
not (cancer or polycystic or exercise or physical() activity or postmenopaus? or oral 
contraceptives, combined)
and body weight/de
limited to human
LILACS (through 1 July 2010)
contraceptive agents or Agentes Anticonceptivos Femeninos or Anticoncepcionais 
Femininos or contraceptive devices, female or Dispositivos Anticonceptivos Femeninos or 
Dispositivos Anticoncepcionais Femininos or contraceptives or Anticonceptivos or 
Anticoncepcionais [Words]
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and weight or body weight or Peso Corporal or weight gain or Aumento de Peso or Ganho 
de Peso or weight reduction or weight loss or Pérdida de Peso or Perda de Peso or body 
weight changes or Cambios en el Peso Corporal or Alterações do Peso Corporal or body 
mass index or BMI [Words]
ClinicalTrials.gov (through 27 April 2010)
Search terms: overweight OR obese OR obesity OR weight OR body mass index OR BMI
Condition: NOT (HIV OR polycystic OR PCOS OR cancer OR anorexia OR pulmonary OR 
metabolic OR amenorrhea)
Intervention: contraceptive OR contraception
Study type: interventional studies
Gender: studies with female participants
ICTRP (through 07 September 2010)
1. Intervention: contraceptive OR contraception
2. Condition: contraceptive OR contraception
Intervention: progestin OR progestin-only OR IUD OR implant OR medroxyprogesterone 
OR norethisterone
Appendix 3. Newcastle-Ottawa Quality Assessment Scale for cohort studies
Note: A study can be awarded a maximum of one star (✴) for each numbered item within 
the Selection and Outcome categories. A maximum of two stars can be given for 
Comparability.
Selection
1. Representativeness of the exposed cohort
a. truly representative of the average ˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙ (describe) 
in the community ✴
b. somewhat representative of the average ˙˙˙˙˙˙˙˙˙˙˙˙˙˙ in the 
community ✴
c. selected group of users eg nurses, volunteers
d. no description of the derivation of the cohort
2. Selection of the non exposed cohort
a. drawn from the same community as the exposed cohort ✴
b. drawn from a different source
c. no description of the derivation of the non exposed cohort
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3. Ascertainment of exposure
a. secure record (eg surgical records) ✴
b. structured interview ✴
c. written self report
d. no description
4. Demonstration that outcome of interest was not present at start of study
a. yes ✴
b. no
Comparability
1. Comparability of cohorts on the basis of the design or analysis
a. study controls for ˙˙˙˙˙˙˙˙˙˙˙˙˙ (select the most important 
factor) ✴
b. study controls for any additional factor✴ (This criteria 
could be modified to indicate specific control for a second 
important factor.)
Outcome
1. Assessment of outcome
a. independent blind assessment ✴
b. record linkage ✴
c. self report
d. no description
2. Was follow-up long enough for outcomes to occur
a. yes (select an adequate follow up period for outcome of 
interest) ✴
b. no
3. Adequacy of follow up of cohorts
a. complete follow up - all subjects accounted for ✴
b. subjects lost to follow up unlikely to introduce bias - small 
number lost - > ˙˙˙˙ % (select an adequate %) follow up, or 
description provided of those lost) ✴
c. follow up rate < ˙˙˙˙% (select an adequate %) and no 
description of those lost
d. no statement
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Figure 1. 
Study flow diagram, 2016
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Figure 2. 
Risk of bias graph: review authors’ judgements about each risk of bias item presented as 
percentages across all included studies.
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Figure 3. 
Risk of bias summary: review authors’ judgements about each risk of bias item for each 
included study.
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Analysis 1.1. 
Comparison 1 Norethisterone 350 µg OC versus levonorgestrel 30 µg OC, Outcome 1 Mean 
weight change (kg) at 6 months.
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Analysis 2.1. 
Comparison 2 Desogestrel (DSG) OC versus control (no hormonal method), Outcome 1 
Mean change in weight (kg) at 1 year.
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Analysis 2.2. 
Comparison 2 Desogestrel (DSG) OC versus control (no hormonal method), Outcome 2 
Mean change in BMI (kg/m2) at 1 year.
Lopez et al. Page 40
Cochrane Database Syst Rev. Author manuscript; available in PMC 2017 August 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Analysis 2.3. 
Comparison 2 Desogestrel (DSG) OC versus control (no hormonal method), Outcome 3 
Mean change in fat mass (%) at 1 year.
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Analysis 2.4. 
Comparison 2 Desogestrel (DSG) OC versus control (no hormonal method), Outcome 4 
Mean change in fat free mass (%) at 1 year.
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Analysis 3.1. 
Comparison 3 DMPA 150 mg/mL versus COC, Outcome 1Weight gain ≥ 1 kg at month 6.
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Analysis 3.2. 
Comparison 3 DMPA 150 mg/mL versus COC, Outcome 2 Weight gain ≥ 1 kg at month 12.
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Analysis 3.3. 
Comparison 3 DMPA 150 mg/mL versus COC, Outcome 3 Weight loss ≥ 1 kg at month 6.
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Analysis 3.4. 
Comparison 3 DMPA 150 mg/mL versus COC, Outcome 4 Weight loss ≥ 1 kg at month 12.
Lopez et al. Page 46
Cochrane Database Syst Rev. Author manuscript; available in PMC 2017 August 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Analysis 3.5. 
Comparison 3 DMPA 150 mg/mL versus COC, Outcome 5 Mean weight change (kg) at 6 
months.
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Analysis 3.6. 
Comparison 3 DMPA 150 mg/mL versus COC, Outcome 6 Mean weight change (kg) at 12 
months.
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Analysis 3.7. 
Comparison 3 DMPA 150 mg/mL versus COC, Outcome 7 Mean percentage weight change 
at 6 months.
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Analysis 3.8. 
Comparison 3 DMPA 150 mg/mL versus COC, Outcome 8 Mean percentage weight change 
at 12 months.
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Analysis 4.1. 
Comparison 4 DMPA 150 mg/mL versus MPA + E2C, Outcome 1 Mean weight change (kg) 
at 6 months.
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Analysis 4.2. 
Comparison 4 DMPA 150 mg/mL versus MPA + E2C, Outcome 2 Mean weight change (kg) 
at 12 months.
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Analysis 4.3. 
Comparison 4 DMPA 150 mg/mL versus MPA + E2C, Outcome 3 Mean percentage weight 
change at 6 months.
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Analysis 4.4. 
Comparison 4 DMPA 150 mg/mL versus MPA + E2C, Outcome 4 Mean percentage weight 
change at 12 months.
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Analysis 5.1. 
Comparison 5 DMPA 150 mg/mL + placebo versus DMPA 150 mg/mL + E2C, Outcome 1 
Mean change in total body fat (%) at 6 months.
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Analysis 5.2. 
Comparison 5 DMPA 150 mg/mL + placebo versus DMPA 150 mg/mL + E2C, Outcome 2 
Mean change in lean body mass (%) at 6 months.
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Analysis 6.1. 
Comparison 6 DMPA 150 mg/mL versus DMPA 450 mg/mL, Outcome 1 Mean weight 
change (kg) at 6 months.
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Analysis 7.1. 
Comparison 7 DMPA 150 mg/mL initiation after pregnancy: interval (≥ 20 weeks) versus 
postpartum (5 to 8 weeks), Outcome 1 Mean weight gain (lb) at 1 year.
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Analysis 7.2. 
Comparison 7 DMPA 150 mg/mL initiation after pregnancy: interval (≥ 20 weeks) versus 
postpartum (5 to 8 weeks), Outcome 2 Mean weight gain (lb) at 2 years.
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Analysis 8.1. 
Comparison 8 DMPA-IM 150 mg versus DMPA-SC 104 mg, Outcome 1 Mean weight 
change (kg) at 36 months.
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Analysis 9.1. 
Comparison 9 DMPA 150 mg/mL versus NET-EN 200 mg (60-day intervals), Outcome 1 
Mean weight change (kg) at 12 months.
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Analysis 9.2. 
Comparison 9 DMPA 150 mg/mL versus NET-EN 200 mg (60-day intervals), Outcome 2 
Mean weight change (kg) at 24 months.
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Analysis 9.3. 
Comparison 9 DMPA 150 mg/mL versus NET-EN 200 mg (60-day intervals), Outcome 3 
Mean weight change at 1 year.
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Analysis 10.1. 
Comparison 10 NET-EN 200 mg: 60-day intervals versus 3 intervals of 60 days then 84-day 
intervals, Outcome 1 Mean weight change (kg) at 12 months.
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Analysis 10.2. 
Comparison 10 NET-EN 200 mg: 60-day intervals versus 3 intervals of 60 days then 84-day 
intervals, Outcome 2 Mean weight change (kg) at 24 months.
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Analysis 11.1. 
Comparison 11 DMPA 150 mg/mL versus Cu IUC, Outcome 1 Mean weight change (kg) at 
10 years.
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Analysis 11.2. 
Comparison 11 DMPA 150 mg/mL versus Cu IUC, Outcome 2 Mean weight change (kg) at 
1 year by baseline BMI.
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Analysis 11.3. 
Comparison 11 DMPA 150 mg/mL versus Cu IUC, Outcome 3 Mean weight change (kg) at 
2 years by baseline BMI.
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Analysis 11.4. 
Comparison 11 DMPA 150 mg/mL versus Cu IUC, Outcome 4 Mean weight change (kg) at 
3 years by baseline BMI.
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Analysis 11.5. 
Comparison 11 DMPA 150 mg/mL versus Cu IUC, Outcome 5 Mean weight change (kg) by 
year.
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Analysis 11.6. 
Comparison 11 DMPA 150 mg/mL versus Cu IUC, Outcome 6 Mean changes in body 
composition by 12 months.
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Analysis 12.1. 
Comparison 12 DMPA, ENG implant, or LNG-IUC versus Cu IUC, Outcome 1 Mean 
weight change (kg) at 1 year.
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Analysis 12.2. 
Comparison 12 DMPA, ENG implant, or LNG-IUC versus Cu IUC, Outcome 2 Mean 
weight change (kg) at 4 years.
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Analysis 12.3. 
Comparison 12 DMPA, ENG implant, or LNG-IUC versus Cu IUC, Outcome 3 Mean 
weight change (kg) at 10 years.
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Analysis 12.4. 
Comparison 12 DMPA, ENG implant, or LNG-IUC versus Cu IUC, Outcome 4 Weight 
change (kg) at 12 months.
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Analysis 13.1. 
Comparison 13 DMPA 150 mg/mL versus no hormonal method, Outcome 1 Mean change in 
total body fat (%) at 6 months.
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Analysis 13.2. 
Comparison 13 DMPA 150 mg/mL versus no hormonal method, Outcome 2 Mean change in 
lean body mass (%) at 6 months.
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Analysis 13.3. 
Comparison 13 DMPA 150 mg/mL versus no hormonal method, Outcome 3 Mean change in 
weight (lb) at 12 months postpartum.
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Analysis 13.4. 
Comparison 13 DMPA 150 mg/mL versus no hormonal method, Outcome 4 Mean change in 
BMI (kg/m2) at 12 months postpartum.
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Analysis 13.5. 
Comparison 13 DMPA 150 mg/mL versus no hormonal method, Outcome 5 Mean change in 
body fat (%) at 12 months postpartum.
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Analysis 14.1. 
Comparison 14 Norplant versus non-hormonal IUC, Outcome 1 Mean weight change (kg) at 
6 months.
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Analysis 14.2. 
Comparison 14 Norplant versus non-hormonal IUC, Outcome 2 Mean weight change (kg) at 
1 year.
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Analysis 14.3. 
Comparison 14 Norplant versus non-hormonal IUC, Outcome 3 Mean weight change (kg) at 
3 years.
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Analysis 15.1. 
Comparison 15 Norplant versus barrier, ’local’, or no contraceptive method, Outcome 1 
Mean weight change (kg) at 6 months.
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Analysis 16.1. 
Comparison 16 Norplant versus DMPA 150 mg/mL, Outcome 1 Mean weight change (kg) at 
1 year.
Lopez et al. Page 85
Cochrane Database Syst Rev. Author manuscript; available in PMC 2017 August 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Analysis 17.1. 
Comparison 17 Norplant versus 2-rod LNG, Outcome 1 Mean weight change (kg) at 1 year.
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Analysis 17.2. 
Comparison 17 Norplant versus 2-rod LNG, Outcome 2 Mean weight change (kg) at 3 years.
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Analysis 17.3. 
Comparison 17 Norplant versus 2-rod LNG, Outcome 3 Mean weight change (kg) at 5 years.
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Analysis 18.1. 
Comparison 18 Norplant versus COC, Outcome 1 Mean weight change (kg) at 1 year.
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Analysis 19.1. 
Comparison 19 LNG-IUC versus no hormonal contraceptive, Outcome 1 Mean changes in 
body composition by 12 months.
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Analysis 19.2. 
Comparison 19 LNG-IUC versus no hormonal contraceptive, Outcome 2 Mean change in 
weight (kg) at 1 year.
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Analysis 19.3. 
Comparison 19 LNG-IUC versus no hormonal contraceptive, Outcome 3 Mean change in 
BMI (kg/m2) at 1 year.
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Analysis 19.4. 
Comparison 19 LNG-IUC versus no hormonal contraceptive, Outcome 4 Mean change in fat 
mass (%) at 1 year.
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Analysis 19.5. 
Comparison 19 LNG-IUC versus no hormonal contraceptive, Outcome 5 Mean change in fat 
free mass (%) at 1 year.
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Table 1
Evidence quality
Study Randomiza-
tion methods or
NRS
NRS: NOS se-
lection criterion
NRS: NOS
comparability
Follow-up
period
Loss or chart re-
view
Evidence qual-
itya
Ball 1991 −1 NA NA −1 −1 Very low
Bonny 2009 −1 - - −1 - Low
Castle 1978 −1 - −1 −1 −1 Very low (poor)
Dal’Ava 2012 −1 - - - - Moderate
Dal’Ava 2014 −1 - - - −1 Low
Dos Santos 2014 −1 - - - −1 Low
Espey 2000 −1 - - - −1 Low
Modesto 2015 −1 - - - −1 Low
Moore 1995 −1 - - - −1 Low
Napolitano 2015 −1 - −1 - - Low
Nyirati 2013 −1 - −1 - −1 Very low
Pantoja 2010 −1 - - - −1 Low
Salem 1984 −1 - −1 −1 - Very low
Salem 1988 - NA NA - −1 Moderate
Sivin 1998 - NA NA - −1 Moderate
Sule 2005 −1 - −1 - −1 Very low
Taneepanichskul 1998 −1 −1 - - −1 Very low
Tankeyoon 1976 −1 - - - −1 Low
Tuchman 2005 −1 - −1 - −1 Very low
Vickery 2013 −1 - - - −1 Low
Westhoff 2007 −1 NA NA - −1 Low
WHO 1983 −1 NA NA - −1 Low
a
Downgraded for the following: (1) Risk of bias high for randomization sequence generation or allocation concealment, or no information provided 
on either, or study not randomized (NRS); (2) NRS: high risk of bias in selection; (3) NRS: no stars for comparability, i.e. not controlling for 
relevant confounding; (4) follow-up < 12 months for change in weight or BMI; (6) loss to follow-up > 20%, combined loss to follow-up and 
discontinuation > 50%, major differential losses between groups, or retrospective chart review of selected cases
NA = not applicable
NOS = Newcastle-Ottawa Quality Assessessment Scale
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Table 3
Results by contraceptive method
Study Comparison groups Mean difference (95% CI) Quality of evidencea
Progestin-only oral contraceptive
Ball 1991 NET 350 μg vs levonorgestrel 30
µg
NS Very low
Napolitano 2015 Desogestrel 75 µg vs no hormonal
contraceptive
Fat mass (%) 3.30 (2.08 to 4.52);
fat-free mass (%) −3.30 (−4.52 to −
2.08)
Low
Depot medroxyprogesterone acetate (DMPA) 150 mg/mL
Comparison: combination contraceptive
Tankeyoon 1976 DMPA vs COC NS Low
Tuchman 2005 DMPA vs COC NS Very low
DMPA vs MPA + E2C NS
Bonny 2009 DMPA + placebo vs DMPA + E2C NS Low
Comparison: another progestin-only injectable formulation or regimen
Castle 1978 DMPA 150 vs DMPA 450 NS Very low (poor)
Espey 2000 DMPA: interval (≥ 20 weeks) vs
postpartum (5 to 8 weeks)
NS Low
Westhoff 2007 DMPA-intramuscular 150 vs
DMPA-subcutaneous 104
NS Low
WHO 1983 DMPA vs NET-EN (60 days) NS Low
NET-EN: 60 days vs 84 days NS
Salem 1988 DMPA vs NET-EN NS Moderate
Comparison: no hormonal contraceptive (retrospective studies)
Taneepanichskul 1998 DMPA vs Cu IUC NS Very low
Pantoja 2010 DMPA vs Cu IUC Weight (kg):
2.28 (1.79 to 2.77);
2.71 (2.12 to 3.30);
3.17 (2.51 to 3.83)
Low
Modesto 2015 DMPA vs Cu IUC Reported mean weights (kg):
1.3 vs 0.2 (P < 0.0001);
3.5 vs 1.9 (P < 0.0001);
6.6 vs 4.9 (P < 0.0350)
Low
Comparison: no hormonal contraceptive (prospective studies)
Vickery 2013 DMPA vs Cu IUC NS Low
Dal’Ava 2014 DMPA vs Cu IUC NS Low
Dos Santos 2014 DMPA vs Cu IUC NS Low
Bonny 2009 DMPA + placebo vs no hormonal Total body fat (%) 11.00 (2.64 to
19.36);
lean body mass (%) −4.00 (−6.93
to −1.07)
Low
Nyirati 2013 DMPA: 6 weeks postpartum vs
sterilization
NS Very low
Implants
Vickery 2013 ENG implant vs Cu IUC NS Low
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Study Comparison groups Mean difference (95% CI) Quality of evidencea
Salem 1984 Norplant vs other non-hormonal Weight (kg) 0.74 (0.52 to 0.96) Very Low
Norplant vs Cu IUC Weight (kg) 0.47 (0.29 to 0.65)
Sule 2005 Norplant vs non-hormonal IUC Weight (kg) 1.10 (0.36 to 1.84) Very low
Norplant vs COC NS
Moore 1995 Norplant vs DMPA NS Low
Sivin 1998 Norplant vs 2-rod LNG NS Moderate
Levonorgestrel-releasing IUC vs no hormonal method
Dal’Ava 2012 LNG-IUC vs non-hormonal IUC Reported mean weights (kg):
Total body fat (%) 2.5 vs −1.3 (P =
0.029);
lean body mass (%) −1.4 vs 1.0 (P =
0.027)
Moderate
Vickery 2013 LNG-IUC vs Cu IUC NS Low
Modesto 2015 LNG-IUC vs Cu IUC NS Low
Napolitano 2015 LNG-IUC vs no contraceptive Fat mass (%) 1.60 (0.45 to 2.75);
fat-free mass (%) −1.60 (−2.75 to −
0.45)
Low
a
From Table 1
Cu IUC: copper intrauterine contraception
COC: combination oral contraception
DMPA: depot medroxyprogesterone acetate
LNG-IUC: levonorgestrel-releasing intrauterine contraception
MPA: medroxyprogesterone acetate
NET: norethisterone
NET-EN: norethisterone enanthate
NS = no significant difference between groups
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SUMMARY OF FINDINGS FOR THE MAIN COMPARISON [Explanation]
DMPA compared with no hormonal contraceptive for effect on weight
Patient or population: women with need for contraception
Settings: clinic
Intervention: DMPA 150 mg/mL
Comparison: no hormonal contraceptive
Outcomes Relative effect
(95% CI)
Participants
(study)
Quality of the evidence
(GRADE)
Comments
Change in body fat (%)
by 6 months;
change in lean body
mass (%) by 6 months
MD 11.00 (2.64 to 19.
36);
MD −4.00 (−6.93 to −1.
07)
26
(Bonny 2009)
Low DMPA + placebo vs no
hormonal;
adolescents 15 to 18
years old
Change in weight (kg):
1 year;
2 years;
3 years
MD 2.28 (1.79 to 2.77);
MD 2.71 (2.12 to 3.30);
MD 3.17 (2.51 to 3.83);
758
(Pantoja 2010)
Low DMPA vs Cu IUC;
women of child-bearing
age
Change in weight (kg):
1 year;
4 years;
10 years
Reported adjusted
mean ± SE (reported P)
:
1.3 ± 0.15 vs 0.2 ± 0.17
(P < 0.0001);
3.5 ± 0.23 vs 1.9 ± 0.23
(P < 0.0001);
6.6 ± 0.61 vs 4.9 ± 0.60
(P < 0.0350)
1277;
1165;
279
(Modesto 2015)
Low DMPA vs Cu IUC;
women 18 to 40 years
old
CI: Confidence interval; MD = mean difference; SD = standard deviation; SE = standard error
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and
may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
DMPA: depot medroxyprogesterone acetate
Cu IUC: copper intrauterine contraception
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ADDITIONAL SUMMARY OF FINDINGS [Explanation]
Levonorgestrel-releasing IUC compared with no hormonal contraceptive for effect on weight
Patient or population: women with need for contraception
Settings: clinic
Intervention: LNG-IUC
Comparison: no hormonal contraceptive
Outcomes by 1 year Relative effect
(95% CI)
Participants
(study)
Quality of the evidence
(GRADE)
Comments
Change in fat mass (%)
;
change in lean mass
(%)
Reported mean ± SD (re-
ported P):
2.5 ± 8.0 vs −1.3 ± 6.9
(P = 0.029);
−1.4 ± 4.7 vs 1.0 ± 3.8
(P = 0.027)
76
(Dal’Ava 2012)
Moderate LNG-IUC vs non-hor-
monal IUC;
women 18 to 45 years
old
Change in fat mass (%)
;
change in fat free mass
(%)
MD 1.60 (0.45 to 2.75);
MD −1.60 (−2.75 to −0.
45)
60
(Napolitano 2015)
Low LNG-IUC vs no contra-
ceptive;
perimenopausal women
CI: Confidence interval; MD = mean difference; SD = standard deviation
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and
may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
IUC: intrauterine contraception
LNG-IUC: levonorgestrel-releasing intrauterine contraception
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OC desogestrel 75 µg compared with no hormonal contraceptive for effect on weight
Patient or population: perimenopausal women with need for contraception
Settings: clinic
Intervention: OC containing desogestrel 75 µg
Comparison: no hormonal contraceptive
Outcomes by 1 year Relative effect
(95% CI)
Participants
(study)
Quality of the evidence
(GRADE)
Change in fat mass (%);
change in fat free mass (%)
MD 3.30 (2.08 to 4.52);
MD −3.30 (−4.52 to −2.08)
68
(Napolitano 2015)
Low
CI: Confidence interval; MD = mean difference
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and
may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
OC: oral contraceptive
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CHARACTERISTICS OF STUDIES
Characteristics of included studies [ordered by study ID]
Ball 1991
Methods Design: randomized controlled trial
Location: likely in Oxford, England
Time frame: no information
Sample size estimation and outcome of focus: no information
Participants 51 women, 17 to 41 years old, requesting oral contraceptives (OC)
Inclusion criteria: new OC users had not used OC or hormone therapy for 3 months;
switchers were changing from low-dose combined OC
Exclusion criteria: hypertension (diastolic blood pressure (BP) > 100 mm Hg, systolic
BP > 140 mm Hg); smoking > 20 cigarettes/day; diabetes
Interventions Progestin-only pills
1 Norethisterone (NET) 350 µg (N = 23)
2 Levonorgestrel (LNG) 30 µg (N = 23)
6 treatment cycles
Outcomes Primary: mean change in weight; lipoprotein levels, glucose tolerance, coagulation fac-
tors, and blood pressure
Time frame: 6 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
Unclear risk No information other than stratified ac-
cording to prior OC use
Allocation concealment 
(selection bias)
Unclear risk No information
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Single-blind (unspecified)
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information; objective outcome mea-
sure
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up: 24% (12/51); analysis
for weight included 39 women at 6 months
(23 NET; 16 LNG)
5 did not return for follow-up and were ex-
cluded (groups not specified); 9 withdrew
after 3 months (1 NET; 8 LNG)
Bonny 2009
Methods Design: prospective study; part of larger 2-year study that examined hormonal contra-
ception and bone mineral density
Location: 4 urban adolescent health clinics in large metropolitan area, likely Cleveland
OH (USA)
Time frame: enrollment 2002 to 2003
Sample size estimation and outcome of focus: no information
Participants Postmenarchal girls 12 to 18 years of age
Inclusion criteria: requesting contraception and selecting DMPA or OC; those who did
not want hormonal contraception were eligible for control group
Exclusion criteria: pregnancy or DMPA use in past 6 months; OC use in past 3 months;
alcohol or drug dependence; medical condition (e.g. renal disease) or medication use
(e.g. corticosteroids) associated with outcomes of interest; contraindication to estrogen
use; weight > 250 lb (upper limit for dual energy x-ray absorptiometry [DEXA] scanner)
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; need for confidential contraceptive care
Interventions Choice of study group
1 Depot medroxyprogesterone acetate (DMPA) (N = 15): randomized to additional 
monthly injections of placebo (N = 8) or estradiol cypionate 5 mg (E2C) (N = 7)
2 Control (no hormonal contraception) (N = 18)
Third group chose OCs (N = 18); not included here. Type of OC not specified; may 
have included progestin-only OCs and combination OCs
Outcomes Percent change in total body fat and in lean body mass
Follow-up: 6 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
High risk NRS: participants chose contraceptive
method
NOS selection (NRS) Low risk Exposed: clinic population; volunteers for
study
Non-exposed: same population as exposed
but chose different contraceptive
Exposure: adherence to DMPA appoint-
ments
NOS comparability (NRS) Low risk Analysis: multivariate models for change
in total body fat and change in lean body
mass; adjusted for potential confounders,
e.g. age, race or ethnicity, caloric intake
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to women having chosen
contraceptive method
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information; objective outcome mea-
sure
Incomplete outcome data 
(attrition bias)
All outcomes
Unclear risk Loss to follow-up: unknown; analysis table
does not specify N
To remain in study, participants had to ad-
here to DMPA by appointment. No infor-
mation on controls
Castle 1978
Methods Design: prospective study
Location: family planning center in Salisbury, Rhodesia
Time frame: enrolment June to December 1976
Sample size estimation and outcome of focus: no information
Participants 1000 women; age range: “under 20” to 40 years or older
Inclusion criteria: Black women seeking contraception at specific clinic
Exclusion criteria: no mention
Interventions 1 DMPA 150 mg every 3 months (N = 500)
2 DMPA 450 mg every 6 months (N = 500)
Outcomes Mean increase in weight
Timeframe: 6 months
Weight measured at each visit while participant wore only a gown
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation 
(selection
bias)
High risk NRS; allocation by participant request
NOS selection (NRS) Low risk Exposed: clinic population; volunteers for
study
Non-exposed: same population as exposed
(different DMPA)
Exposure: injections given during clinic ap-
pointments
NOS comparability (NRS) High risk Analysis: no adjustment
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to women having chosen
contraceptive method
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information; objective outcome mea-
sure
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up: 39% DMPA 150 mg
and 23% DMPA 450 mg; differential losses
between groups
Withdrawals from study: 21 for DMPA
150 mg and 17 for DMPA 450 mg
Dal’Ava 2012
Methods Design: prospective study
Location: single site in Campinas, Brazil
Time frame: enrolled October 2009 to May 2010
Sample size estimation and outcome of focus: based on weight gain in LNG-IUC users
from previous study; 37 needed for each group
Participants 76 women
Inclusion criteria: 18 to 45 years of age; initiated contraceptive use (either LNG-IUC or
Cu T380A IUC)
Exclusion criteria: currently breastfeeding or breastfeeding during 6 months before en-
rollment; used corticosteroids, thiazide diuretics, or drugs for treatment of thyroid dis-
ease; eating disorder; chronic disease
Interventions 1 LNG-IUC (N = 38)
2 Cu T380A IUC (N = 38)
Outcomes Change in weight (kg); percent change in total fat mass, total lean mass, central-peripheral
fat ratio
Follow-up: 12 months
Notes Limitations: physical activity and daily caloric intake were not monitored during study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
High risk Women apparently chose contraceptive
method
NOS selection (NRS) Low risk Exposed: study volunteers; recruitment
methods not specified unclear if they were
clinic attendees
Non-exposed: same population as exposed
but chose non-hormonal IUC
Exposure: clinic inserted IUC
NOS comparability (NRS) Low risk Design: paired by age (± 2 years) and BMI
(± 2 kg/m2) for intervention groups
Analysis: no mention of using control vari-
ables in analysis; listed sociodemographic
variables; obstetric and gynaecologic his-
tory; physical activity; consumption of cof-
fee, alcohol, milk; smoking; family history
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of osteoporosis
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to women having chosen
contraceptive method
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information; objective outcome mea-
sure
Incomplete outcome data 
(attrition bias)
All outcomes
Low risk Loss to follow-up: no discontinuation at 12
months
Dal’Ava 2014
Methods Design: prospective matched
Location: single site in Campinas, Brazil
Time frame: enrolled October 2009 to June 2011
Sample size estimation and outcome of focus: reported change in baseline percentage of
body fat 12 months after initiation of contraception (primary outcome), 1.75% increase
in DMPA users vs 0.31% reduction in Cu IUC users; required 20 complete cases in each
group, using repeated measures ANOVA with 5% significance level and 80% power
Participants 97 women
Inclusion criteria: 18 to 50 years of age; new DMPA or Cu IUC users
Exclusion criteria: breastfeeding; use of DMPA in prior 6 months; history of diabetes,
pituitary disorder, liver or kidney disease, cancer; use of corticosteroids, diuretics, hor-
mone therapy; eating disorder
Interventions 1 DMPA 150 mg (N = 55)
2 Cu T380A IUC (N = 42)
Outcomes Change in weight (kg), fat mass (kg), and lean mass (kg)
Follow-up: 12 months
Notes Women using Cu IUC may overlap with those in Dal’Ava 2012; study periods overlap
and inclusion criteria are similar. Unable to obtain further information from investigator
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
High risk Participants chose method
NOS selection (NRS) Low risk Exposed: volunteered for study; unclear if
they were clinic attendees
Non-exposed: same population as exposed
but chose different contraceptive method
Exposure: clinic records (inserted IUC and
administered DMPA)
NOS comparability (NRS) Low risk Design: paired by age (± 2 years) and weight
(± 2 kg) for intervention groups
Analysis: control variables of physical ac-
tivity, consumption of coffee and alcohol,
smoking in regression; reportedly not sig-
nificant
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to women having chosen
contraceptive method
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No mention; objective outcome measure
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up and discontinuation:
DMPA 53% (29/55); IUC 24% (10/42)
From IUC group, only 26 of 32 matched
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with 26 in DMPA group
Major differential losses between groups
Dos Santos 2014
Methods Design: prospective matched
Location: Campinas, Brazil
Time frame: enrolled February 2011 to February 2013
Sample size estimation and outcome of focus: none; exploratory study
Participants 71 women
Inclusion criteria: age 18 to 40 years; BMI < 30; never used DMPA; fasting glucose <
100 mg/dL and glucose level < 140 mg/dL at 120 minutes after 75 g oral glucose load
Exclusion criteria: breastfeeding; family history of first-degree relative with diabetes mel-
litus; type 1 or 2 diabetes, metabolic syndrome, hypertension, hyper- or hypothyroidism,
chronic renal failure, hirsutismor hyperandrogenism, polycystic ovary syndrome or acan-
thosis nigricans; transplant recipient; had undergone bariatric surgery
Interventions 1 DMPA 150 mg intramuscular (IM) (N = 44)
2 Cu T380A IUC (N = 27)
Outcomes Change in body weight, total fat mass, percent body fat, and total lean mass; change in
bone mineral density
Follow-up: 12 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
High risk Women chose method
NOS selection (NRS) Low risk Exposed: clinic population, volunteered for
study
Non-exposed: same population as exposed
but chose different contraceptive
Exposure: clinic records; clinic inserted
IUC and administered DMPA
NOS comparability (NRS) Low risk Design: paired for age (± 1 year) and BMI
(± 1 kg/m2)
Analysis: multiple linear regression in-
cluded age, weight, BMI, schooling, skin
color, social class, pregnancies, deliveries,
smoking, alcohol, coffee (secondary report
Modesto 2014)
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to women having chosen
contraceptive method
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No mention; objective outcome measures
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up and discontinuation:
overall 24% (17/71); DMPA 34% (15/44)
and CU IUC 7% (2/27)
Major differential losses across groups
Espey 2000
Methods Design: retrospective chart review
Location: 3 Indian Health Service facilities in southwestern USA
Time frame: first injection of DMPA from December 1992 to June 1995
Sample size estimation and outcome of focus: no information
Participants Female members of Navajo tribe
Inclusion criteria: 18 to 40 years old; completed at least 5 consecutive injections of
DMPA at 10- to 14-week intervals; had weights recorded at 1- or 2-year intervals
Exclusion criteria: history of diabetes or thyroid disease; women in postpartum group
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who had pre-eclampsia or multiple gestations within index pregnancy
Interventions DMPA initiation
1 Interval (N = 115): first injection ≥ 20 weeks past pregnancy of ≥ 20 weeks gestation
2 Postpartum (N = 57): first injection at 5 to 8 weeks after delivery of singleton 
pregnancy of ≥ 20 weeks gestation
Outcomes Mean weight gain (lb) for DMPA by initiation group
Time frame: 1 and 2 years
Notes For another group, not included in this review, investigators reportedly extracted method
of contraception from charts but did not provide specifics. Discussion noted that group
“more frequently used” IUC or tubal ligation and included COC users
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
High risk DMPA users by choice
NOS selection (NRS) Low risk Exposed: clinic population of Navajo
women
Non-exposed: same population as exposed
Exposure: clinic records of DMPA injec-
tions
NOS comparability (NRS) Low risk Analysis: adjusted for age, parity, and initial
weight
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to differences in insertion
times
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information; objective outcome mea-
sure
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up: for 1 year, only com-
plete records included in retrospective re-
view; does not account for discontinuation
and loss; at 2 years, no weight data for 70%
of interval group and 49% of postpartum
group
Modesto 2015
Methods Design: retrospective chart review
Location: Campinas, Brazil
Time frame: 1990 to 2010
Sample size estimation and outcome of focus: based on difference in weight between
DMPA users and non-users; for alpha 5% and beta error 20% using repeated measures
ANOVA, 700 required for each group
Participants 2138 women
Inclusion criteria: 18 to 40 years of age; started using DMPA, Cu IUC or LNG-IUC in
1990 and used uninterruptedly for 10 years; Cu IUC and LNG-IUC users monitored
annually at clinic and DMPA users attended clinic every 90 days for injection
Exclusion criteria: chronic medical disease including dyslipidemia, diabetes, thyroid dis-
ease, and renal failure; history of bariatric surgery or organ transplant; LNG-IUC use
for other than contraception
Interventions 1 DMPA 150 mg IM (N = 714)
2 Cu IUC (N = 723)
3 LNG-IUC (N = 701)
Outcomes Mean weight gain (kg)
Time frame: 1 year and 10 years
Notes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
High risk Women chose method; charts reviewed un-
til 700 met eligibility criteria for each group
NOS selection (NRS) Low risk Exposed: clinic population, using contra-
ceptive method for 10 years, beginning in
1990
Non-exposed: same population as exposed
but chose different contraceptive
Exposure: clinic records (clinic inserted
IUC and administered DMPA)
NOS comparability (NRS) Low risk Analysis: generalized linear mixed model
adjusted for years of school and number of
children
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to women having chosen
contraceptive method
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No mention; objective outcome measure
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up: retrospective review of
charts with relevant data; does not account
for discontinuation and loss
Overall loss: at 1 year 12% (DMPA 5%,
LNG-IUC 14%, Cu IUC 17%); at 4 years
19% (DMPA 24%, LNG-IUC 20%, Cu
IUC 14%); at 10 years 84% (DMPA 82%,
LNG-IUC 90%, Cu IUC 79%)
Moore 1995
Methods Design: retrospective chart review
Location: rural obstetrics and gynecology clinic in Arizona (USA)
Time frame: no information
Sample size estimation and outcome of focus: none; selected 50 women in each group
who met inclusion criteria
Participants 150 women, 15 to 30 years old
Inclusion criteria: users of OCs, Norplant, or DMPA
Exclusion criteria: prior hormonal contraceptive therapy; height < 62 inches (152.4 cm)
or > 70 inches (177.8 cm); weight < 100 lb (45.5 kg) or > 180 lb (81.8 kg); presence of
diabetes; history of thyroid disease; < 12 months postpartum
Interventions 1 Norplant (N = 50)
2 DMPA 150 mg (N = 50)
Third group of OC users excluded from this review; type of OC not specified and 
may have included progestin-only OCs and combination OCs
Outcomes Weight gain (kg)
Timeframe: 1 year
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
High risk Women presumably chose contraceptive
method; charts reviewed until 50 met eli-
gibility criteria for each group
NOS selection (NRS) Low risk Exposed: rural clinic population
Non-exposed: same population as exposed
but used different contraceptive
Exposure: clinic records
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NOS comparability (NRS) Low risk Analysis: model adjusted for age, height,
weight, and parity at beginning of study
period
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible because women presumably
chose contraceptive method
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information; objective outcome mea-
sure
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up: retrospective review of
charts with relevant data; does not account
for discontinuation and loss
Napolitano 2015
Methods Design: prospective study
Location: menopause clinic in Italy
Time frame: enrolled January 2011 to January 2014
Sample size estimation and outcome of focus: based on prior experience, 11 subjects
needed per group to document between-group difference in fat mass (FM) of 1.2 kg ±
0.6; no power analysis reported
Participants 110 women
Inclusion criteria: perimenopausal based on serum FSH > 15 IU/ml and irregular men-
strual cycles or amenorrhea < 3 months (aged 45 to 55 years)
Exclusion criteria: current hormone use; sterilization; BMI < 18 or > 30; vascular disease
or coagulation disorder; hypersensitivity to study drug ingredient; thyroid dysfunction;
fasting glucose > 110 mg/dl; breast or gynecologic disease
Interventions 1 Desogestrel (DSG) 75 µg OC (N = 44)
2 LNG-IUC (N = 35)
3 Control, no contraception (N = 31)
Outcomes Change in weight (kg), BMI, fat mass (%), fat free mass (%), waist (cm), waist to hip
ratio, resting metabolic rate (kJ/24 h)
Follow-up: 12 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
High risk Women chose method
NOS selection (NRS) Low risk Exposed: menopause clinic population,
volunteered for study
Non-exposed: same population as exposed
Exposure: clinic records (clinic inserted
IUC)
NOS comparability (NRS) High risk Analysis: unadjusted
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to women having chosen
contraceptive method
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No mention; objective outcome measure
Incomplete outcome data 
(attrition bias)
All outcomes
Low risk Loss to follow-up or discontinuation: 7%
(8/110); DSG OC 4.5% (2/44), LNG-
IUC 3% (1/35), and control 16% (5/31);
control had 2 lost to follow-up (6%)
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Nyirati 2013
Methods Design: prospective study using convenience sample
Location: large Midwestern city, possibly Columbus OH (USA)
Time frame: 18-month period, specific dates not given
Sample size estimation and outcome of focus: not reported; body composition changes
at 1 year postpartum
Participants 78 postpartum women
Inclusion criteria: ≥ 18 years of age; elected to use DMPA or surgical sterilization
Exclusion criteria: hormone replacement therapy, e.g. OC, thyroid hormone, steroid
therapy; significant prenatal and postpartum medical illness including gestational or type
II diabetes; BMI > 35
Interventions 1 DMPA 150 mg every 12 weeks, beginning at 6 weeks postpartum (N = 61)
2 Surgical sterilization and no other contraceptive (N = 17)
Outcomes Change in weight (lb), BMI, fat%, body dimensions (fat folds and circumferences) from
6 weeks to 1 year postpartum
Follow-up: every 3 months for 1 year
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
High risk Women chose method
NOS selection (NRS) Low risk Exposed: clinic population; postpartum
women
Non-exposed: same population as exposed
but chose different contraceptive
Exposure: clinic records (clinic adminis-
tered DMPA)
NOS comparability (NRS) High risk Analysis: no adjustment for potential con-
founding of outcome measures
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to women having chosen
contraceptive method
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No mention; objective outcome measure
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up or discontinuation:
DMPA 43%(26/61); sterilization 29%(5/
17)
Pantoja 2010
Methods Design: retrospective chart review
Location: university department of obstetrics and gynecology in Campina, Brazil
Time frame: chart data from January 1991 to December 2000
Sample size estimation and outcome of focus: difference in weight between DMPA users
and nonusers using analysis of variance for repeat measures; based on mean increase in
fat mass in users, 150 DMPA users estimated; significance 5% and power 80%
Participants Women who accepted contraceptive method
Inclusion criteria: chose DMPA and used continuously ≥3 years or who used Cu T380A
for similar time period (mean age 29 years)
Exclusion criteria: diabetes mellitus; hyperthyroidism or hypothyroidism; chronic renal
failure; rheumatic diseases requiring chronic use of corticoids; organ transplant
Interventions 1 DMPA (N = 379)
2 Cu T380A IUC (N = 379)
After pairing for age and baseline BMI, 379 for each contraceptive group
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Outcomes Change in weight (kg) by contraceptive group and by baseline BMI (kg/m2) (< 25; 25
to 29.9; ≥ 30)
Time frame: 1, 2, and 3 years
Weight and height measured at baseline (method initiation) and annually
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
High risk Women chose contraceptive method
NOS selection (NRS) Low risk Exposed: clinic attendees
Non-exposed: same population as controls
but chose different contraceptive
Exposure: from clinic records
NOS comparability (NRS) Low risk Design: paired for age and baseline BMI
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to women having chosen
contraceptive method
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information; objective outcome mea-
sure
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up: chart review of those
with 3 years continuous use; does not ac-
count for discontinuation and loss
Salem 1984
Methods Design: prospective study; focused on effect of Norplant use on lactating women and
on lactation performance and infant growth
Location: postpartum clinic of university hospital in Assiut, Egypt
Time frame: no information
Sample size estimation and outcome of focus: no information; recruited 50 women for
each group
Participants 150 lactating women; mean age 29 years
Inclusion criteria: normal delivery of normal living baby and exclusively breastfeeding;
1 month after delivery; infant weight ≥ 3500 gm
Exclusion criteria: no mention
Interventions Acceptors (50 in each group)
1 Norplant
2 Barrier, ’local’ or no contraceptive method
3 Cu T380A IUC
Outcomes Weight gain by study group
Follow-up: 6 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
High risk Women apparently chose contraceptive
method
NOS selection (NRS) Low risk Exposed: attendees at postpartum clinic;
volunteered to participate
Non-exposed: same population and time-
frame as controls but chose different con-
traceptive
Exposure: obtained during monthly fol-
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low-up visits
NOS comparability (NRS) High risk Analysis: no adjustment
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to women having chosen
contraceptive method
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information; objective outcome mea-
sure
Incomplete outcome data 
(attrition bias)
All outcomes
Low risk Loss to follow-up: only those excluded (1
Norplant group, lost baby and wanted to
get pregnant; 2 pregnancies in group with
barrier, ’local’, or no contraceptive)
Salem 1988
Methods Design: randomized controlled trial; examined performance of 2 injectables regarding
side effects, continuation, and termination
Location: family planning center in Assiut, Egypt
Time frame: no information
Sample size estimation and outcome of focus: no information
Participants 400 women attending family planning clinic
Inclusion criteria: 18 to 40 years old; proven fertility and frequent risk of pregnancy;
regular menstrual cycles; willing to rely on one method
Exclusion criteria: breast-feeding; cardiovascular disease; liver disease; known or sus-
pected breast malignancy, genital malignancy, uterine fibroids; undiagnosed vaginal
bleeding; suspected pregnancy
Interventions 200 in each group
1 DMPA 150 mg every 3 months
2 Norethisterone enanthate (NET-EN) 200 mg every 2 months
Outcomes Mean change in weight by contraceptive group; units not specified (kg or lb)
Follow-up: 1 year
Report had mean change for those with increase, decrease, or no change in weight
We calculated combined weight change means and standard deviations
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
Low risk Random numbers table prepared by WHO
Allocation concealment 
(selection bias)
Low risk Sealed envelopes contained assignments
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to different injection
schedules
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information; objective outcome mea-
sure
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up: reportedly 19% for
DMPA and 13.3% for NET-EN
One-year method continuation rates: 68.
8% DMPA and 57.1% NET-EN
Finished study: 54% DMPA and 47%
NET-EN
Sivin 1998
Methods Design: randomized controlled trial; focused on effectiveness of reformulated 2-rod LNG
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implant versus 6-rod implant
Location: 7 centers including USA and Finland
Time frame: enrollment 1990 to 1994
Sample size estimation and outcome of focus: assumed 50/100 acceptors would continue;
pregnancy rate 2.0/100 at 3 years with SE 0.66/100; sample size could distinguish
difference in pregnancy of 2/100 between 2 implant types
Participants 1200 healthy women, 18 to 40 years old, who sought implant contraception
Inclusion criteria: no contraindication to implant use; willing to undergo study proce-
dures
Exclusion criteria: cancer; severe cardiovascular problem; hyperlipidemia; diabetes melli-
tus; mental illness; epilepsy; severe or frequent headaches; undiagnosed genital bleeding;
hyperprolactinemia or bloody breast discharge; pelvic inflammatory disease since last
pregnancy or ectopic pregnancy
Interventions Levonorgestrel implants
1 Norplant: 6 capsules containing levonorgestrel 216 mg (total)
2 LNG rod (Jadelle): 2 rods containing levonorgestrel 150 mg (total); different 
elastomer in core than earlier implant
Follow-up: 1, 3, 6 months; then semi-annually to 5 years
Outcomes Mean weight change by implant group
Weight change for 10th, 50th, and 90th percentiles of body weight (at admission)
Follow-up: 5 years
Weighing method not specified
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
Low risk Randomization by “linear congruential
method”; blocks of 50 per clinic
Allocation concealment 
(selection bias)
Low risk Implants in sealed opaque envelopes num-
bered sequentially according to randomiza-
tion lists
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to apparent differences in
interventions
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information; objective outcome mea-
sures
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up: year 3, 2.7% each group;
year 5, 7.2% LNG rod and 10.2% Nor-
plant
Discontinuation: end of year 3, LNG rod
31.6% (190/600) and Norplant 31.2%
(187/598); end of year 5, LNG rod 54.7%
(328/600) and Norplant 60% (359/598)
2 sets of Norplant contaminated and not
used (1198/2000 analyzed)
Sule 2005
Methods Design: retrospective chart review
Study examined hormonal contraceptives and weight changes.
Location: family planning clinic of university hospital in Zaria, Nigeria
Time frame: registered from 01 January 1993 to 31 December 1995
Sample size estimation and outcome of focus: no information
Participants 516 new clients
Inclusion criteria: used hormonal contraceptive (COC, injectable (DMPA or NET-EN)
, Norplant); non-hormonal IUC users as controls; followed for ≥ 1 year (mean age
hormonal users 30.5 years and non-hormonal IUD 29.1 years)
Exclusion criteria: used barrier methods; had bilateral tubal ligation; chose no contra-
ceptive method
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Interventions Method users
1 Norplant (N = 188)
2 non-hormonal IUC (N = 136)
Outcomes Mean weight gain or loss by contraceptive group
Time frame: 1 and 3 years
Report had mean change for those with increase, decrease, or no change in weight. We
calculated combined weight change means and standard deviations
Notes Injectable users not used in this review; DMPA and NET-EN had been grouped for
analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
High risk Users of contraceptive method; women
presumably chose method
NOS selection (NRS) Low risk Exposed: clinic attendees
Non-exposed: same population as exposed
but chose different contraceptive
Exposure: clinic records
NOS comparability (NRS) High risk Analysis: no adjustment
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to women presumably
having chosen method
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information; objective outcome mea-
sure
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up: investigators selected
charts with ≥ 1 year of data, so no loss by
1 year; by 3 years, overall loss by 3 years
of 54% (Norplant 31%; COC 95%; IUC
56%)
Taneepanichskul 1998
Methods Design: retrospective study examined weight change in long-term users of DMPA versus
IUC
Location: family planning clinic at a hospital in Bangkok, Thailand
Time frame: no information
Sample size estimation and outcome of focus: no information
Participants 100 women, age 37 to 50 years, attending family planning clinic
Inclusion criteria: used DMPA or IUC for 120 months (10 years); followed “regularly”;
no history of smoking or alcohol intake
IUC users had not used any hormonal contraceptive
Exclusion criteria: developed chronic disease or metabolic disorder during DMPA or
IUC use
Interventions Method chosen
1 DMPA (N = 50)
2 Cu T380A IUC (N = 50)
Outcomes Mean change in body weight
Time frame: 120 months
Weight measured in standard manner at 120 months; prior method not specified
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation 
(selection
bias)
High risk Users of DMPA “recruited randomly”;
users of Cu T380A selected as controls
NOS selection (NRS) High risk Exposed: clinic population, older contra-
ceptive users; used method for 10 years and
regularly attended clinic
Non-exposed: same as exposed group but
chose different contraceptive
Exposure: presumably from clinic records
NOS comparability (NRS) Low risk Design: matched for age, parity, income,
weight
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to women presumably
having chosen method
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information; objective outcome mea-
sure
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up: retrospective study of
women who used method for 10 years
and regularly attended clinic; may have re-
cruited women with relevant data in charts
Exclusions: developed chronic disease or
disorder during method use; may have bi-
ased results because weight gain is asso-
ciated with development of some diseases
and disorders
Tankeyoon 1976
Methods Design: prospective metabolic study; focused on metabolic effects of contraceptive meth-
ods
Location: Bangkok, Thailand
Time frame: no information
Sample size estimation and outcome of focus: no sample size calculation; focused on
metabolic effects of contraceptive methods
Participants 32 healthy women attending the family planning clinic; age 18 to 38 years
Inclusion criteria: > 6 weeks postpartum and no other steroid use for past 3 months
Exclusion criteria: no information
Interventions 1 DMPA 150 mg (3-month intervals) (N = 16)
2 COC: d-norgestrel 50 µg + EE 50 µg (N = 16)
Outcomes Percent of cases with ≥ 1 kg increase or decrease in body weight by contraceptive method
Follow-up: 1, 2, 3, 6, 9, 12 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
High risk Women receiving contraceptive method;
presumably chose method
NOS selection (NRS) Low risk Exposed: clinic population, volunteered for
study
Non-exposed: same as exposed group but
chose different contraceptive
Exposure: presumably from clinic records
NOS comparability (NRS) Low risk Analysis: adjusted for pretreatment value
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to women presumably
having chosen method
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Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information; objective outcome mea-
sure
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up: 19% by 12 months;
DMPA 2/16 (13%) and COC 4/16 (25%)
Differential losses between groups though
sample sizes are small
Reasons for missing data not specified
Tuchman 2005
Methods Design: retrospective chart review
Location: urban, hospital-based, teen health center (USA)
Time frame: enrollment 01 January 2001 to 31 December 2001
Sample size estimation and outcome of focus: no sample size calculation; emphasis on
weight change
Participants 222 females, aged 12 to 21 years, attending health center for contraception
Inclusion criteria: first-time use of oral or injectable contraceptive
’New start’ defined as no OC in past 3 months or DMPA in past 6 months prior to new
method initiation
Exclusion criteria: no other information
Interventions Choice of method
1 DMPA every 3 months
2 Medroxyprogesterone acetate + estradiol cypionate 5 mg (MPA + E2C) monthly
3 COC
Outcomes Mean weight change (kg) and mean percent weight change by contraceptive method
Time frame: 3, 6, 9, 12 months
Standardized weight and height measures described.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
High risk Young women presumably chose contra-
ceptive method
NOS selection (NRS) Low risk Exposed: clinic population of new users
Non-exposed: same as exposed group but
chose different contraceptive
Exposure: clinic records
NOS comparability (NRS) High risk Analysis: no adjustment for weight out-
come
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to differences in inter-
ventions and women presumably chose
method
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information; objective outcome mea-
sure
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up or discontinuation: may
have selected charts with relevant data for
retrospective review; at 12 months, discon-
tinuation 54% to 58%
Vickery 2013
Methods Design: substudy of CHOICE (see Notes below)
Location: St. Louis, MO (USA)
Time frame: enrolled between June 2009 and May 2011
Sample size estimation and outcome of focus: for weight change (kg) at 12 months,
assumed mean weight gain 0.6 kg over 12 months in Cu IUC users and 2.0 kg in
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progestin-only users; assumed alpha 0.05, power 80%, and SD 3.0 kg in all groups;
needed 73 women in each arm; for SD of 5.0 kg for Cu IUC and 6.0 kg for progestin-
only users, increased sample size to 100 in Cu IUC group and 130 in progestin-only
groups
Participants 427 women enrolled in CHOICE
Inclusion criteria: 18 to 45 years old; continuous user for ≥ 11 months of LNG-IUC,
Cu IUC, implant, or DMPA; enrolled at university research site; had height and weight
measured at enrollment visit
Exclusion criteria: did not speak English; < 18 years old; metabolic disorder known to
affect body weight, e.g. hypothyroidism or diabetes
Interventions 1 DMPA (N = 67)
2 LNG-IUC (N = 130)
3 Cu IUC (N = 100)
4 ENG implant (N = 130)
Outcomes Weight change (kg)
Follow-up: 12 months
Notes CHOICE, prospective cohort study of 9256 women: promote the use of LARC, remove
financial barriers by providing contraceptives at no cost, and evaluate method continu-
ation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
High risk Women selected method of contraception
NOS selection (NRS) Low risk Exposed: clinic population; volunteered to
participate in substudy
Non-exposed: same population as exposed
but chose different contraceptive
Exposure: clinic records (inserted IUC or
ENG implant and administered DMPA)
NOS comparability (NRS) Low risk Analysis: stratified by race (associated with
weight change); final adjusted linear regres-
sion model included age (LNG-IUC and
Cu-IUC users were slightly older) as well as
covariates associated with outcome and ex-
posure and those that altered effect ≥ 10%
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to women having chosen
contraceptive method
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No mention; objective outcome measure
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up: selected women who
completed 11 months of use; 35% of
women screened met eligibility criteria
(749/2145), of which 57% enrolled (427/
749)
Westhoff 2007
Methods Design: analysis of data from 3 RCTs
Location: sites in North and South America
Time frame: no information
Sample size estimation and outcome of focus: no information
Participants 534 women, 18 to 49 years old, sexually active and wanting long-term contraception
Inclusion criteria: no OC use for past 2 months; regular menstruation in past 3 months;
willing to rely on DMPA for year
Exclusion criteria: used OCs, implants, or hormonal IUC in past 2 months or DMPA-IM
in past 10 months; pregnant or infertile; abnormal Pap; undiagnosed genital bleeding;
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other contraindications to hormonal contraceptives
Interventions 1 DMPA-SC 104 mg (N = 266)
2 DMPA-IM 150 mg (N = 268)
Injections every 3 months for 3 years
Outcomes Weight change (as safety endpoint)
Follow-up: 36 months
Notes Investigators also analyzed weight change by BMI group: ≤ 25; 25 to 30; > 30 kg/m2.
Report notes no consistent differences by BMI groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
Unclear risk No information
Allocation concealment 
(selection bias)
Unclear risk No information
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to differences in interven-
tions (intramuscular vs subcutaneous)
Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information for 2 trials; evaluator
blinded in 1 trial, but unclear if relevant to
weight outcome
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up or discontinuation:
DMPA-SC 24% (201/266); DMPA-IM
79% (212/268); reasons for discontinua-
tion unclear
WHO 1983
Methods Design: phase III randomized controlled trial
Location: 13 centers in Africa, Asia, Central and South America, and Europe
Time frame: recruitment began 1977; final follow-up March 1982
Sample size estimation and outcome of focus: no information
Participants 3172 women; mean age 27.4 years
Inclusion criteria: non-breastfeeding women who chose injectable contraception
Exclusion criteria: contraindication for long-acting contraceptive methods
Interventions 1 DMPA 150 mg at 90-day intervals (N = 1587)
2 Norethisterone enanthate (NET-EN) 200 mg at 60-day intervals (N = 789)
3 NET-EN 200 mg at 60-day intervals for 6 months then 84-day intervals (N = 796)
Outcomes Mean weight change by contraceptive group
Follow-up: 12 and 24 months
Notes Method for measuring weight not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation 
(selection
bias)
Unclear risk “Randomly allocated”
Allocation concealment 
(selection bias)
Unclear risk No information
Blinding of participants and 
personnel
(performance bias)
All outcomes
Unclear risk Not feasible due to differences in injection
schedules for interventions
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Blinding of outcome 
assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data 
(attrition bias)
All outcomes
High risk Loss to follow-up: reportedly 10.7%
DMPA; 8.9% NET-EN 60 days; 9.8%
NET-EN 84 days
Life-table rates for total discontinuation:
71% to 74%
BMI: body mass index
DMPA: depot medroxyprogesterone acetate
FSH: follicle stimulating hormone
LNG-IUC: levonorgestrel-releasing intrauterine contraception
MPA: medroxyprogesterone acetate
NET-EN: norethisterone enanthate
NRS: non-randomized study
OC: oral contraceptive
SD: standard deviation
Cochrane Database Syst Rev. Author manuscript; available in PMC 2017 August 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lopez et al. Page 122
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agoestina 1978 Insufficient weight change data: presented in figure without any specific numbers, other than mean gain
for DMPA group in text
Bahamondes 2010 Mean weight change not reported. BMI included as control variable for examining bone mineral density
Study examined weight change among participants who had been using the method (LNG-IUC) for at
least 7 years before the study
Barsivala 1974 Insufficient data: study duration not reported (our criteria was ≥ 3 months); also, investigators did not
specify whether the variance reported is standard deviation or standard error
Beksinska 2010 Analysis combined users of DMPA, NET-EN, or both. Investigators noted the subgroups were too small
to analyze separately and that differences in weight gain were not significant
Berenson 1997 Insufficient weight change data: means reported without any variance measure
Berenson 2009 Insufficient weight change data: mean change reported without any variance.
Of 240 who chose DMPA, 60% discontinued the method by 12 months and 76% discontinued by 36
months. DMPA users with > 5% weight increase at 6-month visit were more likely lost to follow-up by
next visit than those who had not gained such weight
Secondary report (Rahman 2012) provided weight gain (by kg categories) over any 6-month period;
categories overlapped
Bonny 2006 Analysis combined groups that received DMPA + placebo or DMPA + estradiol supplement; reportedly
DMPA groups did not differ in weight gain
DMPA discontinuation 37% at 18 months; data from 2000 to 2003
Bonny 2011 Not comparative
Bonny 2015 Not comparative
Casey 2013 Insufficient data: no weight change reported
Chen 2011 Abstract notes that weight gain was reported as side effect. Wrote to investigator regarding whether weight
change was measured. Unable to obtain further information
Clark 2005 Insufficient weight change data: means (not mean change) presented in a figure. Text mentions mean
change for DMPA at 30 months (no variance measure) and that the control group was basically unchanged.
Due to discontinuations of DMPA and initiation of hormonal contraception among controls, the samples
sizes were 17% (DMPA) and 19% (controls) of baseline by the last visit
Costa 2012 Mean change in weight was not reported. Participants were 1.5 months postpartum
Dahlberg 1982 Insufficient weight change data: means reported without any variance measure
El Mahgoub 1980 Insufficient weight change data: mean change reported without any variance measure. Also, percent that
lost or gained weight was reported, but no specific amount of weight was provided
Gallo 2016 Two arms: immediate and delayed insertion of Sino-Implant II. Secondary analysis of data from RCT that
examined condom use. Delayed group was offered OC prescription; no information on how many used it
Hall 1980 Insufficient weight change data: mean change in ’ideal body weight’ shown in figure, except for mean
change for progestin-only group reported in text
Havranek 1972 Insufficient weight data: mean change for one group reported without any variance measure
Hernandez-Juarez 2014 Insufficient weight data; weight change not reported
Kaunitz 2009 Insufficient weight data. Mean change was reported within adverse event section without any variance
measure. Data from 2001 to 2004
Mangan 2002 Comparison groups were DMPA users and OC users. Types of OC were not specified and might have
included progestin-only as well as combination OC
Modesto 2014b Insufficient data: counseling only; no weight change measured
Nault 2013 Insufficient data: weight gain not broken down by contraceptive type
Olsson 1988 Insufficient data for analysis: no N per group for analysis. First-year continuation rate was 59% for Norplant
and 77% for Norplant-2; methods suggest these were life-table rates
Ortayli 2001 Insufficient data: report does not provide sample sizes used for analysis. Outcome data are from a pilot
conducted in 1995 and the main study conducted from 1996 to 1998
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Study Reason for exclusion
Risser 1999 Comparison groups were DMPA users and OC users. Types of OC were not specified and might have
included progestin-only as well as combination OC
Segall-Gutierrez 2012 Single-arm study comparing normal weight and obese women. The one intervention was subcutaneous
DMPA
Veisi 2013 Insufficient weight data: self-reported weight only
WHO 1978 Insufficient weight data: mean gains reported without any variance measure
Yela 2006 Insufficient weight change data: tables show weight and BMI means (not change) by year; text mentions
mean change per group over 5 years without any variance measure. Study began in 1998
Zheng 1999 Insufficient weight change data: means reported without any variance measure
BMI: body mass index
DMPA: depot medroxyprogesterone acetate
LNG-IUC: levonorgestrel-releasing intrauterine contraception
NET-EN: norethisterone enanthate
OC: oral contraceptive
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Characteristics of studies awaiting assessment [ordered by study ID]
Madden 2014
Methods Design: observational prospective cohort; non-probability sample
Purpose: learn if women gain weight using progestin-only methods of contraception and if so, how much
Location: St Louis, MO (USA)
Time frame: April 2010 to August 2014
Sample size estimation and outcome of focus: no information
Participants 345 women
Inclusion criteria: aged 18 to 45 years; starting copper IUC or implant through provider; first study visit must occur
within 14 days of method insertion
Exclusion criteria: DMPA in past 16 weeks; POPs, LNG-IUC, or implant in past 4 weeks; thyroid disease, autoim-
mune disease, diabetes (excluding gestational); history of eating disorder; currently taking antidepressants for < 6
months, antipsychotics; oral glucocorticoids (steroids, i.e. prednisone) for > 6 months; currently breastfeeding or <
6 months postpartum
Interventions 1 Levonorgestrel-containing intrauterine contraceptive (LNG-IUC)
2 Etonogestrel (ENG) subdermal implant
3 Copper IUC
Outcomes Primary: weight change; BMI change
Secondary: body composition, including fat mass and percentage and central-to-peripheral fat ratio
Body composition with dual-energy x-ray absorptiometry (DEXA); diet and activity via validated questionnaires
Follow-up: 12 months
Notes Will consider for inclusion when full report is available
Schreiber 2014
Methods Design: randomized; open label; mixed methods
Location: Philadelphia PA (USA)
Time frame: April 2011 to October 2012
Sample size estimation and outcome of focus: no information
Participants 100 women
Inclusion criteria: English-speaking; age 18 to 45 years; immediately postpartum of live singleton infant, 37 weeks
gestation; desire to delay another pregnancy for next 6 months; willing and able to follow protocol
Exclusion criteria: breastfeeding; plans to relocate outside of Philadelphia area in next 6 months; plans for use of
weight loss medication or diet pills in next 6 months; wish to use Implanon or DMPA prior to discharge but does
not want to be randomized
Interventions 1 DepoProvera (DMPA) 150 mg
2 Implanon; 68 mg etonogestrel
3 Control: select own method of contraception or no contraception
Outcomes Primary: weight change by 6 months postpartum
Secondary: pregnancy; contraception satisfaction
Follow-up: 3, 6, and 12 months postpartum
Notes Will consider for inclusion when full report is available
BMI: body mass index
DMPA: depot medroxyprogesterone acetate
LNG-IUC: levonorgestrel-releasing intrauterine contraception
POP: progestin-only oral pills
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Characteristics of ongoing studies [ordered by study ID]
Bonny 2016
Trial name or title Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects
Methods Design: randomized, open-label; pharmacokinetic study
Purpose: learn whether DMPA affects weight gain and bone mineral density in teens
Location: Columbus, OH (USA)
Time frame: September 2011 to April 2015
Sample size estimation and outcome of focus: no information
Participants 45 healthy young women
Inclusion criteria: healthy, postmenarchal females; age 12 to 21 years; self-selected to initiate DMPA; willing
to use barrier method of contraception in addition to DMPA
Exclusion criteria: chronic disease known to affect weight or bone mineral density (BMD) (e.g. diabetes,
kidney); medication known to affect weight or BMD (e.g. corticosteroids); DMPA use in past 12 months;
pregnancy in past 6 months; etonogestrel implant, LNG-IUC or combined contraceptive in past 3 months
(OC, transdermal patch, vaginal ring); weight > 450 lb; need for confidential contraceptive care for individuals
< 18 years of age
Interventions DMPA, intramuscular injection
• 150 mg; approved for use (US Food and Drug Administration (FDA)) when given into muscle
• 104 mg; FDA-approved for use only when given under the skin; considered experimental
• 75 mg; considered experimental; not FDA-approved regardless of how given
Outcomes Primary: > 5% weight gain at 24 weeks
Secondary: > 10% weight gain at 48 weeks
Follow-up: 24 and 48 weeks
Starting date September 2011; planned completion April 2016
Contact information Andrea Bonny, MD; Nationwide Children’s Hospital; Columbus, Ohio (USA)
Notes
Halpern 2017
Trial name or title Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods
Methods Design: randomized, multicenter, open label
Location: Portland OR (USA); Santo Domingo, Dominican Republic
Time frame: September 2015 to August 2017
Sample size estimation and outcome of focus: no information
Participants 48 women
Inclusion criteria: in good general health; aged 18 to 40 years; willing to provide consent and follow study
requirements; negative urine pregnancy test on day of injection; does not become pregnant in next 24 months;
regular menstrual cycle (27 to 35 days); confirmed ovulation in 2 consecutive samples during pre-treatment
phase; low risk of pregnancy; BMI 18 to 35; hemoglobin ≥ 10.5 g/L
Exclusion criteria: medical contraindication to DMPA use; use of any investigational drug, prohibited drugs,
OCs, LNG-IUC or implant within 1 month prior to enrollment; use of DMPA in past 12 months; use of
combined injectable contraceptive in past 6 months; recent pregnancy (within 3 months); current lactation;
ongoing or anticipated use of prohibited drugs; known sensitivity to MPA; plan to move to another location
in next 18 months
Interventions 1 1 subcutaneous injection of 150 mg/mL DMPA in abdomen
2 1 subcutaneous injection of 300 mg/mL DMPA in abdomen
3 2 injections of 104 mg/0.65 mL DMPA in abdomen, given at 3-month intervals
Outcomes Primary: time to ovulation
Secondary: weight at follow-up; Cmax; aggregate of individual Cmax measurements and parameters; adverse
events
Follow-up: 18 months
Starting date September 2015; planned completion August 2017
Contact information Vera Halpern, MD: FHI 360; vhalpernfhi360.org; 919-544-7040 x11390
Notes
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DMPA: depot medroxyprogesterone acetate
LNG-IUC: levonorgestrel-releasing intrauterine contraception
MPA: medroxyprogesterone acetate
Cochrane Database Syst Rev. Author manuscript; available in PMC 2017 August 28.
